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ABSTRACT 
Using Proteomics to 1) Identify the Bone Marrow Homing Receptors Expressed on 
Human Hematopoietic Stem Cells and 2) Elucidate Critical Signaling Pathways 
Responsible for the Blockage of Hematopoietic Differentiation in Leukemia 
Chin Chee Jia 
 
Successful hematopoiesis requires the trafficking of hematopoietic 
stem/progenitor cell (HSPCs) to their bone marrow (BM) niche, where they can 
differentiate to produce all blood lineages. Leukemia arises when there is a blockage of 
differentiation and uncontrolled proliferation in the hematopoietic cells during their 
development. To refine therapies for leukemia, this study sought to improve the homing 
of healthy donor HSPCs for better transplantation and to find new candidates for 
differentiating and blocking proliferation in leukemic cells.  
Characterizing the molecular effectors mediating cell migration forms the basis 
for improving clinical transplantation of HSPCs. E-selectin/ligand interactions play a 
critical role in the homing of HSPCs to the BM, however, the identity of E-selectin 
ligands remains elusive. We aimed to use mass spectrometry (MS) to fully analyze the E-
selectin ligands expressed on HSPCs. Immunopercipitation studies coupled with MS 
confirmed the expression of three known E-selectin ligands, the hematopoietic cell E-/L-
selectin ligand (HCELL), P-selectin glycoprotein ligand-1 (PSGL-1) and CD43, and 
revealed the presence of many interesting candidates on HSPCs-like cell line and on 
primary human BM CD34
+
 cells. The MS dataset represents a rich resource for further 
characterization of E-selectin ligands, which will lead to improvement of HSPCs 
transplantation.  
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 Understanding the critical pathways underlying the initiation and maintenance of 
leukemia plays a key role in treating acute myeloid leukemia (AML). Ligation of the 
glycoprotein, CD44, using monoclonal antibodies or its natural ligand, hyaluronic acid, 
drives the differentiation of immature leukemic cells towards mature terminally 
differentiated cells, inhibits their proliferation and in some case induces their apoptosis. 
The aim of this study is to characterize the phosphoproteome of AML cells in response to 
CD44-induced differentiation. This will afford novel insights into the signaling events 
critical for proliferation and differentiation in AML cells. Stable isotope labeling with 
amino acids in cell culture is used to quantify the changes in the global phosphorylation 
profile upon CD44 activation.  Preliminary results showed that the heavy isotope was 
fully incorporated and that anti-CD44 induction of myeloid differentiation was not 
perturbed in our culture conditions. We anticipate that this study will bring forth new 
candidates for a targeted therapy of AML. 
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CHAPTER I:  Analysis of Glycoprotein E-selectin Ligands Expressed on Human 
Hematopoietic Progenitor Cells 
Chee Jia Chin 
INTRODUCTION 
 In the multi-step paradigm of cell migration, cells that are travelling at high-
velocity within the bloodstream slow down and enter specific tissues/organs by relying 
on the interactions among specific molecules expressed on their surface and on surface of 
the vascular endothelium.  Every step in this process is a prerequisite to the next and if 
any of the molecules involved in a particular step are absent, the paradigm is jeopardized 
and the cell will remain in circulation.  The initial step in this process is known as 
“tethering and rolling” (Figure 1) (step 1) and is mediated principally by a group of 
adhesion molecules called the selectins. The engagement of selectins with the appropriate 
ligands effectively slows down the cell motion.  The deceleration of the cells on the 
endothelial layer then triggers a cascade of successive molecular interactions such as the 
expression of chemokines on the surface of the endothelium and the activation of 
integrins on the surface of the migrating cells (step 2). This activation induces a 
conformational change in the integrins, causing them to bind with high affinity to their 
ligand(s) on the endothelium resulting in firm adhesion (step 3), arrest and subsequently 
transendothelial migration of the cells into the tissue/organ (step 4).  Thus, the initial 
transient force provided by the selectins is essential for directing and priming the cells for 
tissue entry.  
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Figure 1. The multi-step model of hematopoietic stem/progenitor cells (HSPCs) homing. 
Four distinct steps have been described in the process of cell migration, which involve 
the orchestrated actions from different classes of adhesion molecules: In step 1, tethering 
and rolling are initiated principally by the selectins. These events trigger chemokine 
receptor engagement and G-protein-coupled “inside-out” activation of integrins (step 2), 
resulting in firm adhesion (step 3) and subsequently transmigration of the cells (step 4). 
 
 Decades of research have gone into seeking strategies to deliver cells to a 
predetermined site (ie. tissue or organ of interest).  In particular, research focused on 
studying how HSPCs enter the bone marrow (BM) is of major clinical interest due to its 
implications in modern hematopoietic transplantation.  A critical challenge still facing the 
clinical use of HSPCs for regenerative therapy is to obtain efficient colonization of these 
cells to their rightful home within the bone marrow microenvironment (Sackstein, 2004).  
During transplantation, HSPCs are injected intravenously into the peripheral blood and 
must thereby find their way to the bone marrow and establish a home within the proper 
niche.  This niche will provide the signals needed for the HSPCs to self-renew and 
differentiate and in doing so help to repair the diseased host‟s defective hematopoietic 
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system.  In fact it is only those HSPCs that correctly home to the BM that are able to give 
rise and achieve long term hematopoiesis (Hoggatt and Pelus, 2010).  
 The lack of hematopoietic engraftment is a compounding challenge for patients 
receiving HSPCs transplantation, leaving them to suffer at the hand of infectious diseases 
(e.g. cytomegalovirus disease) and a high risk of disease recurrence, especially for 
malignant disease like leukemia.  It is evident that optimizing vascular delivery of 
hematopoietic stem cells to the requisite sites is imperative to achieve long-term cure.  
Understanding the mechanisms of HSPCs homing, especially the molecular effectors that 
initiate the tethering interactions will bring insights to improve the recruitment efficiency 
of HSPCs to their target sites.    
 The most effective mediators in the initial rolling events are the selectins – E-, P- 
and L- selectin.  They are integral membrane glycoproteins that function in a calcium-
dependent manner to bind discrete sialofucosylated moieties expressed on their respective 
ligands.  Among the selectins, E-selectin/ligand interaction demonstrates the strongest 
adhesion property in terms of the capability to resist detachment under hydrodynamic 
shear force assay (Sackstein, 2009). 
 E-selectin is constitutively expressed on the bone marrow microvasculature while 
its ligands can be found on the HPSCs (Schweitzer et al., 1996) (Figure 2a). This ligand 
recognition is mediated by tetrasaccharide moieties called the sialyl Lewis X (sLeX), 
which is a carbohydrate moiety comprised of an α(2,3)-linked sialic acid to galactose 
(Gal) and an α(1,3)-linked fucose to N-acetylglucosamine (GlcNAc) of a lactosamine 
unit ([Gal-GlcNAc]n) (Figure 2b).  Although the adhesive interactions between E-selectin 
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and sLeX are transient, it is sufficient to selectively slow down the HSPCs among a large 
population of other fast-flowing cells, thereby permitting subsequent extravasation into 
the BM microenvironment (Sackstein, 2004). 
 
Figure 2. The role of E-selectin in HSPCs‟ recruitment to the BM niche. (a) The low 
affinity binding of E-selectin to its ligands bearing the sLeX carbohydrate determinant 
initiates rolling and tethering of HSPCs onto the bone marrow endothelial cells. (b) 
Structure of sLeX.  Pertinent linkages are labeled on the structures. Different shapes refer 
to the types of monosaccharide. Galactose (Gal), Fucose (Fuc), N-acetylglucosamine 
(GlcNAc), N-acetylneuraminic acid (NeuAc). 
 
 To date, the characterization of E-selectin ligands have been extensively 
performed on leukocytes but its functional counterparts on HSPCs remain elusive.  
Among the arrays of E-selectin ligands, only two have been described to be relevant on 
HSPCs: hematopoietic cell E-/L-selectin ligand (HCELL) and cutaneous lymphocyte 
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antigen (CLA).  A recent study has uncovered an additional sialomucin, CD43, as E-
selectin ligand on HSPCs (Merzaban et al., Blood 2011). 
 HCELL has the highest potency in binding E-selectin as demonstrated by shear 
force-based assays (Dimitroff et al., 2001).  With predominant expression on HSPCs, 
HCELL is a specialized glycoform of CD44.  CD44 is an extremely heterogenous and 
pleiotropic molecule, with more than 20 known splice forms and can also be subjected to 
a wide range of post-translational modifications including glycosylation. One key aspect 
distinguishing HCELL from its core protein, CD44, is that its carbohydrate portion 
principally contributes to ligand function.  Treatment with glutaraldehyde, a crosslinking 
fixative that markedly alters protein conformation, did not affect the ligand activity.  In 
other words, the protein backbone is essentially inert to the ligand function.  Indeed, 
ligand activity was abrogated when the carbohydrate moieties were altered, with either 
inhibitors of glycosylation or digestion with sialidase/fucosidase (Oxley and Sackstein, 
1994).  
 Expressed on early hematopoietic cells and the majority of leukocytes, P-selectin 
glycoprotein ligand-1 (PSGL-1) functions as homodimer that is connected by disulfide 
bridges.  Depending on the glycosylation pattern, PSGL-1 can be recognized by all three 
selectins.  Its specific glycoform, „CLA‟, serves as the E-selectin ligand. The sLeX 
moiety is attached to CLA via O-linked glycosylation sites (Sackstein, 2009).  
 CD43 is expressed exclusively on hematopoietic cells.  Long known to be one of 
the most abundant T-cell surface proteins, CD43 was recently shown to collaborate with 
PSGL-1 as E-selectin ligands in facilitating T cell migration into inflamed skin 
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(Matsumoto et al., 2007).  An unsuspected role for CD43 on HSPCs emerges from a 
recent study as demonstrated with immunopercipitation experiment coupled with western 
blot (Merzaban et al., Blood 2011). 
 Given the limited knowledge we have regarding the cognate E-selectin ligands 
expressed on HSPCs, this study aims to use mass spectometry-based proteomics to allow 
full characterization of the available ligands.  Results from the biochemical studies and 
mass spectometry analysis confirmed the presence of HCELL and CD43 on HSPCs while 
revealing a bewildering array of additional ligands, the majority of which have no 
previous implication as E-selectin ligands.  Collectively, the data reveals the structural 
diversity in the protein scaffolds capable of displaying sLeX. These rather surprising 
findings provide a rich resource for further investigation.  
 
 
 
  
18 
 
MATERIALS AND METHODS 
Cells and Antibodies: 
 KG1a, a human AML-derived HSPC-like CD34
+
 cell line, was purchased 
(ATCC, Manassas, VA) and cultured as previously described (Dimitroff et al., 2001). 
Bone Marrow (BM) CD34
+
 cells were purchased from Stem Cell Technologies. 
 The following antibodies were purchased from BD Pharmingen (San Jose, CA): 
rat anti-human sLeX (clone: HECA-452; isotype: IgM), mouse anti-human PSGL-1 
(KPL-1; IgG1), mouse anti-human CD44 (515; IgG1), mouse anti-human CD43 (1G10 
and L60; IgG1), biotin Goat Anti Rat Ig, Streptavidin-Horseradish Peroxidase (HRP). 
The following reagent and antibodies were purchased from R&D Systems: Recombinant 
mouse E-selectin/human immunoglobulin chimera (E-Ig) and mouse anti-human CD44 
(2C5; IgG1). Goat Anti-Mouse IgG, IgM (H+L) ImmunoPure Antibody, Horseradish 
Peroxidase conjugated was purchased from Thermo Scientific. 
Immunoprecipitation (IP) Studies: 
 BM CD34
+
 cells and KG1a cells were lysed using 1% Triton X (Sigma Aldorich) 
in 150mM NaCl, 50mM Tris Base, pH 8, 20 μg/ml phenylmethanesulfonyl fluoride 
(Sigma Aldorich) and protease inhibitor cocktail tablet (Roche Molecular Biochemicals, 
Indianapolis, IN). For E-selectin IP, an additional 2mM CaCl2 was added to the lysis 
buffer. Cells were washed three times with ice-chilled phosphate buffer saline and 
centrifuged at 1400rpm at 4
o
C for 5 minutes using microcentrifuge (Eppendorf) between 
each wash. Then, the cells were lysed for 1 hour at 4
o
C under constant rotation, followed 
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by centrifugation at 13200rpm at 4
o
C for 15 minutes. The collected lysate was precleared 
by incubating with Dynabeads® Protein G (Invitrogen) three times. 30ul of Dynabeads 
was used for every pre-clearing step. Lysate were then incubated with antibodies (each at 
3 μg) or recombinant protein (E-Ig, 10ug) for 1 h at 4°C under constant rotation. The 
antibody–lysate mixture was added to 40 μl of Dynabeads® Protein G and incubated for 
2 h at 4°C under constant rotation or pulse vortex. The supernatant was collected for 
further analysis on the efficiency of the IP while the remaining beads-antibody-antigen 
complex was washed three times with lysis buffer (200ul/wash). Then the complex was 
resuspended in 100ul lysis buffer and transferred to a clean tube. The complex was then 
resuspended in 30ul lysis buffer and 10ul of 4X Laemmli buffer (8% sodium dodecyl 
sulfate (SDS), 20% 2-mercaptoehtanol, 40% glycerol, 0.008% bromophenol blue, 0.25 M 
Tris HCl, pH 6.8), followed by 10 minutes heating at 70°C. The resulting sample was 
subjected to SDS-PAGE, transferred to PVDF membrane, and immunostained with the 
specified antibodies. For exhaustive IPs, two rounds of CD44 IP were performed, 
followed by two rounds of PSGL-1 IP, followed by two rounds of CD43 IP. Western blot 
was performed to confirm the complete removal of all three glycoproteins. E-selectin IP 
was performed on the remaining supernatant to examine evidence for additional ligands.  
Western Blot Analysis:  
 Samples were prepared as described above and sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) was performed using 4-20% Criterion 
Tris-HCl gels (Bio-Rad Laboratories, Hercules, CA) for 1h at 100V. The proteins were 
subsequently transferred to polyvinylidene diflouride (PVDF) membrane (Bio-Rad 
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Laboratories) at 250V, 0.39A for 1:30h. The membrane was then blocked with Tris 
Buffer Saline Tween-20 (20mM Tris, 137mM NaCl, 0.1% Tween-20, PH 7.6) containing 
10% non-fat milk 1h at room temperature. Following that, the membranes were 
immunostained with primary antibodies of interest followed by incubation with 
appropriate HRP-conjugated secondary antibodies. Blots were visualized with 
chemiluminescence using SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific). 
Mass spectrometry Sample Preparation: 
 Proteins were analyzed by mass spectrometry as described (Acestor et al., 2009). 
Briefly, the E-Ig IP samples were separated on 4-20% SDS-PAGE gels and protein bands 
were visualized by SimplyBlue Safe Stain (Invitrogen). Each gel lane was divided into 
four pieces, the proteins were reduced, alkylated and digested in-gel with sequencing 
grade modified trypsin (Promega). The resulting peptides were extracted using buffer A: 
5% acetonitrile (VWR), 95% water, 0.1% formic acid (Sigma-Aldrich). Speed Vacuum 
was used to dry the peptide until approximately 1ul sample volume. The peptides were 
fractionated by nano-flow LC and analyzed using a LTQ Orbitrap Mass Spectrometer 
(Thermo Scientific). Raw data were converted to Mascot Generic Format files and 
searched using the online Mascot database. Carbamidomethyl cysteine and oxidized 
methionines were set as variable modifications. The mass tolerance of the precursor ion 
was 10 parts per million (ppm) and 0.6 dalton (Da) for fragment ions. 
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RESULTS 
Exhaustive IP revealed the presence of new E-selectin ligand(s) on KG1a 
 IP coupled with western blot were first carried out on KG1a, a human 
hematopoietic cell line, to verify the presence of the expected ligands HCELL, PSGL-1, 
and CD43 and to examine if there were any additional E-selectin ligands.  KG1a is a 
leukemia patient-derived, HSPC-like CD34
+
 cell line, so it serves as a great in vitro 
model system to characterize the primitive hematopoietic cells.  
Successive rounds of IP were performed to pull out CD44, PSGL-1 and CD43 
from the KG1a cell lysate.  Specifically, the IP for each glycoprotein was performed 
twice to make sure that it was depleted.  Western blots of these IP samples were probed 
with HECA-452, a monoclonal antibody recognizing sLeX.  In addition, these 
membranes were stripped and re-probed with the corresponding antibodies to confirm 
that the glycoproteins being immunopercipitated were indeed HCELL, PSGL-1 and 
CD43.  
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Figure 3. Western blot from exhaustive IP samples probed for HECA-452 reactivity and 
their corresponding antibodies.  Two rounds of CD44 IP were followed by two rounds of 
PSGL-1 IP, followed by two rounds of CD43 IP.  The supernatants after the second IPs 
were analyzed to check for residual glycoprotein.  HECA-452 is a rat monoclonal 
antibody recognizing sLeX.  
 
 As shown in Figure 3, in the CD44 IP, HECA-452 signal was detected 
(MW~85KDa) in the 1st round of CD44 IP.  No HECA-452 signal was detected in the 
2nd round of CD44 IP, suggesting the specific glycoform HCELL was depleted.  
Immunoblot with anti-CD44 further confirmed that the single band observed in the 
HECA-452 blot corresponded to CD44.  
In the PSGL-1 IP, the HECA-452 signal was detected (~120KD) in the 1st round 
of IP and a faint HECA-452 signal was still detected in the 2nd round of IP.  However, 
when PSGL-1 antibody was used, PSGL-1 was only detected in the 1
st
 round of IP. This 
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suggested that the HECA-452 signal in the 2
nd
 round of IP did not come from PSGL-1.  
All PSGL-1 was already pulled down in the 1
st
 round of IP.  
 In the CD 43 IP, the HECA-452 signal was detected at ~115KD and 130KD in the 
1st round of IP, which corresponds to the two known glycoforms of CD43 (Jones et al., 
1994).  A HECA-452 signal was still detected at MW~130KD in the 2nd round of CD43 
IP. To our surprise, the supernatant after exhaustive IP also displayed HECA-452 
reactivity, suggesting the presence of additional E-selectin ligands.  Another possibility 
was that the IP for CD43 was incomplete, so the HECA-452 signal in the supernatant 
could correspond to residual CD43. To confirm the presence of additional ligands, an E-
selectin recombinant protein (E-Ig) was used as a probe to “fish out” the unknown 
ligand(s) from the remaining supernatant.  E-Ig is a mouse E-selectin protein fused to 
human IgG1.  Figure 4 shows the HECA-452 blot from this E-Ig IP, along with an IP 
performed on the original lysate as positive control, in which HCELL, PSGL-1 and CD43 
were still present. 
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Figure 4. Western blot from E-selectin IP probed for HECA-452 reactivity.  2nd round of 
E-Ig IP refers to the IP performed on the supernatant after exhaustive IP of CD44, PSGL-
1 and CD43 (as shown in Figure 3).  E-Ig IP was also performed on the original lysate 
before exhaustive IP to serve as a positive control. 
  
 A single prominent band of HECA-452 reactivity was detected (MW~130KD) in 
the 2
nd
 round of E-Ig IP.  This might correspond to the unknown ligand(s) that we wish to 
seek or it might merely be the E-Ig recombinant protein itself, which was used as a probe 
in this IP.  
The above data confirmed the presence of HCELL, PSGL-1 and CD43 as E-
selectin ligands on KG1a and suggested the existence of previously unknown ligand(s).  
To resolve this ambiguity and to maximize the efficiency of ligand identification, MS 
was performed to fully analyze all samples pulled down from the E-Ig IP. 
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Mass spectometry analysis revealed new and unique E-selectin ligand candidates 
 Before MS analysis was carried out, western blots were performed to determine 
which KG1a subclone expressed the highest HECA-452 signal. The original KG1a cell 
line received from ATCC displayed a heterogeneous HECA-452 expression profile when 
analyzed by flow cytometry (Figure 6a).  Since E-selectin ligands are HECA-452 
positive, using cells which express more HECA-452 signal maximizes the chance of 
identifying E-selectin ligands. To select for KG1a cells that have high HECA-452 
expression, serial dilution was carried out to propagate KG1a starting from 1 cell/well. 
KG1a was diluted starting from 1x10
5
cells/ml down to 10 cell/ml (Figure 5a). 100ul/well 
(= 1 cell) were seeded into a 96-well plate and the cells were left to propagate for 2-3 
weeks so that the subclones could grow out (Figure 5b). HECA-452 expression from each 
subclone was examined using fluorescence-activated cell sorting (FACS) (Figure 6). 
FACS plots of three subclones were shown to illustrate the divergence in HECA-452 
signal after serial dilution. Some subclones with high HECA-452 expression were further 
examined by Western blot. As shown in Figure 7, lysate from subclone named "RS Clone 
(5/12/08)" showed the highest HECA-452 reactivity and was thus chosen as a positive 
control for subsequent E-selectin IP experiments.    
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Figure 5. KG1a was serially diluted to isolate clones with high HECA-452 expression. 
(a) The dilution was carried out starting from 1x10
5
cells/ml down to 10 cell/ml and 100ul 
was seeded into a 96-well plate to obtain 1cell/well. (b) The clones were cultured for 2-3 
weeks before screening of HECA-452 expression by FACS. 
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Figure 6. HECA-452 expression was examined by FACS on serially diluted KG1a 
subclones. The subclones were first stained with HECA-452, followed by incubation with 
phycoerythrin (PE)-conjugated secondary antibody (goat anti rat Ig). (a) The original 
KG1a is a heterogeneous cell population with differential HECA-452 expression. (b,c,d) 
Examples of high HECA-452 expressing subclones isolated from the original KG1a cell 
population.  
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Figure 7. SDS-PAGE followed by immunoblot with HECA-452 was performed on lysate 
of KG1a subclones available in our lab. The original KG1a cell line displayed an overall 
weak HECA-452 signal because it comprises of a heterogeneous cell population. The 
“RS Clone (5/12/08)" displayed the highest HECA-452 signal. 
 
 E-Ig IP experiments were carried out on the chosen KG1a subclone and on bone 
marrow CD34+ (BM CD34+) cells (isolated from bone marrow healthy donors and 
provided by Stem Cell Technologies).  The IP products were ran on an SDS-PAGE and 
the gel was cut into four small bands.  Proteins extracted from each band were sent for 
MS analysis. The LTQ Orbitrap Mass Spectrometer was used to perform high resolution 
identification of proteins existing in dynamic range.  Table 1 highlights the results 
generated from the MS analysis.  The whole experiment was repeated twice and 
consistent protein candidates were included in the final dataset.  In the E-Ig IP performed 
on KG1a, CD44, CD43 and PSGL-1 showed up in the dataset as expected.  CD44 and 
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CD43 showed up as E-selectin ligands on the BM CD34+ cells.  PSGL-1 was not 
detected, which might be due to the low cell number used as starting material for the IP. 
Interestingly, many other proteins were identified with P value < 0.01, of which the 
majority has not yet been implicated as E-selectin ligands.  Among these were CD34, 
FMS-like tyrosine kinase 3 receptor (FLT3), galectins and the Notch family proteins.  
The significance of these candidates will be discussed further in the following section.  
The complete version of the dataset is available in the Appendix. 
 
Table 1. Highlights of mass spectometry data obtained from the E-selectin IP performed 
on KG1a and bone marrow CD34+ cells 
 
 
Note: Known function of the proteins is summarized in brackets. 
 
Western blots of CD34 IP on KG1a showed E-selectin and HECA-452 reactivity 
 In order to confirm some of the potential E-selectin ligands obtained from MS 
analysis, chosen candidates were IPed from KG1a and probed for the presence of E-Ig 
and HECA-452 reactivity. A preliminary experiment (n=1) was set out to verify if CD34, 
a candidate that consistently showed up in the MS analysis, is indeed an E-selectin 
30 
 
ligand. As shown in Figure 8, a single prominent band of HECA-452 reactivity was 
detected (MW~120KD), matching with the known molecular weight of CD34. When this 
membrane was stripped and re-probed with E-selectin, the same band was also 
recognized by E-selectin. Although signal from the E-selectin probe was faint, this 
nonetheless provides a promising lead that CD34 may be an E-selectin ligand. Follow-up 
experiments will further investigate and confirm the functional relevance of CD34 in 
mediating the tethering and rolling of HSPCs on BM.  
 
 
Figure 8. Western blot of CD34 IP probed for E-selectin and HECA-452 reactivity. 
CD34 was immunoprecipitated from a lysate of KG1a cells aud subjected to western blot.  
The resulting membrane was blotted with HECA-452. The membrane was then stripped 
and re-probed with E-Ig. HECA-452 reactivity was detected at 120kDa, matching with 
the size of CD34. This band was also weakly E-Ig reactive, which suggested CD34 to be 
an E-selectin ligand.    
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SUMMARY 
 Understanding the molecular processes underlying stem cell trafficking is 
important for modern hematopoietic transplantation, of which success relies on the 
efficient homing, engraftment and repopulation of stem cells in the bone marrow.  E-
selectin–ligand interactions play a major role in the initial capturing of HSPCs that travel 
in the high velocity blood flow, allowing activation of subsequent molecular effectors 
responsible for firm adhesion and extravasation.  Knowing that E-selectin is 
constitutively expressed on the marrow vasculature, this study has sought to elucidate the 
E-selectin ligands expressed on HSPCs.  Immunopercipitation studies coupled with 
western blots confirmed the presence of the three known glycoproteins, HCELL, PSGL-1 
and CD43 on KG1a, a cell line that serves as model for primitive hematopoietic cells. 
Residual HECA-452 reactivity was detected in the supernatent after IP pull-down of the 
three known glycoproteins, suggesting the existence of additional E-selectin ligand(s). 
Mass spectometry analysis on the E-selectin IP samples from both KG1a cell line and 
primary BM CD34
+
 cells revealed a large number of potential candidates as E-selectin 
ligands, many of which have not been previously implicated as selectin ligands. 
 The result reveal potential structural diversity on the protein scaffold that carries 
the characteristic sialylfucosylation. The data suggests that E-selectin–binding 
carbohydrate moieties can be attached to different protein scaffolds.  Three interesting 
candidates that emerged from the mass spec analysis, CD34, galectins and FLT3, are 
discussed below. 
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 CD34 consistently showed up as an E-selectin ligand candidate from both 
analyses on KG1a cell line and on primary BM CD34
+
 cells.  CD34 is a transmembrane 
glycoprotein constitutively expressed on endothelial cells and on hematopoietic stem 
cells (HSCs).  It is well known as a marker for human HSCs and as an L-selectin ligand 
important in tethering lymphocytes.  The significance of CD34 in HSPCs homing was 
demonstrated recently.  Mouse CD34
null
 HSCs displayed a five-fold lower engraftment 
when injected into wild type mice (Nielsen and McNagny, 2009).  Interestingly, the 
authors hypothesizes that CD34 serves to block cell adhesion, in the sense that CD34 
may serve to block nonspecific adhesions and repulse HSPCs away from the vascular 
wall, thereby facilitating HSPCs to flow smoothly in circulation until they reach their 
requisite site.  In another study, L-selectin has been implicated as an E-selectin ligand on 
neutrophils. Biochemical analysis showed that the binding of L-selectin to E-selectin was 
abolished by sialidase-treatment and was Ca
+2
 dependent, further suggesting L-selectin as 
a direct ligand for E-selectin (Zoellner et al., 1997). Preliminary results from this study 
confirmed E-selectin and HECA-452 reactivity on the CD34 IP. Since CD34 plays a pro-
adhesive role in directing lymphocytes to the lymph node, and one of its known 
glycosylation pattern with sulfated sLeX is highly similar to the carbohydrate 
determinant that E-selectin recognizes, it is very likely that CD34 expressed on HSPCs 
can also serve as E-selectin ligand in directing homing to the BM.  
 Galectins, like selectins, are another type of sugar-binding molecule. Galectins 
have high structural similarity and share partially overlapping binding specificities. They 
are involved in many diverse cellular functions.  For example, galectins expressed on 
subsets of T helper cells have been implicated in regulating T-cell homeostasis upon 
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binding to its ligand (Rabinovich et al., 2007).  By modulating different regulatory 
checkpoints during T-cell development, the galectins-ligand interaction could either 
amplify or silence immune responses. In terms of cell adhesion, Galectin 3 and 9 were 
shown to be required for early adhesion and long term binding in Madin-Darby canine 
kidney (MDCK) cells (Friedrichs et al., 2007). Since these galectins can interact with a 
broad spectrum of ligands, they have been implicated to function as versatile cross-
linkers of glycosylated cell surface molecules. In our analysis of E-selectin IP samples, 
Galectin 1 was detected in the MS analysis on KG1a while Galectin 9 was in the BM 
cells. It is possible that galectins expressed on HSPCs function to bind and cross link 
multiple E-selectin receptors that are expressed on the BM endothelium. This will 
effectively increase the chance for other E-selectin ligands to engage with E-selectin, thus 
enhancing the step 1 tethering interactions.  
 Constitutive activation of FLT3 is a genetic alteration associated with AML. 
Since FLT3 mutations are among the most common somatic mutations in AML, 
occurring in 20–35% of adult, mutational status of FLT3 has been established as clinical 
guidelines for classification and diagnosis of AML patients (Rosen et al., 2010).  FLT3 
has been reported to functionally interact with C-X-C chemokine receptor type 4 
(CXCR4), the chemokine receptor responsible for activating integrins during firm 
adhesion. When human HSPCs were transfected with transgene overexpressing FLT3 
and transplanted into the nonobese diabetic severe combined immunodeficient 
(NOD/SCID) mice, migration to the bone marrow was significantly reduced (Jacobi et 
al., 2010). It is possible that FLT3 also functions as an E-selectin ligand to induce 
tethering prior to engaging with chemokine receptors in the step 2 of HSPCs homing. If 
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FLT3 can interact with both E-selectin and chemokine receptors, its mutational status in 
AML might be correlated with an enhanced ability of the leukemic cells to home to the 
bone marrow microenvironment. 
 Even though all three proteins above have not been associated with E-selectin 
ligand function, their known functions have been implicated in aspects of cell migration 
and hematopoiesis, which are highly relevant to the process of HSPCs' homing to the 
bone marrow.  Further follow-up experiments are necessary in defining the functional 
relevance of these candidates.  One example of these studies is the blot-rolling assay, 
which examines if a protein will support E-selectin binding in a dynamic (flow based) 
condition (Figure 9).  In this assay, cells expressing human E-selectin are flowed on top 
of a PVDF membrane containing the protein candidate of interest, thus simulating the 
scenario of HSPCs' rolling on BM (Sackstein, 2009). The presence of tethering and 
rolling interactions can be observed by video microscopy. This method assesses adhesion 
under varying shear conditions, thus capable of discriminating and elucidating those 
membrane molecules that are functionally relevant in physiological conditions. 
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Figure 9. Blot-rolling assay as a follow-up experiment to test functional relevance of the 
candidate E-selectin ligands under dynamic flow conditions. Shown in this figure are the 
components in this assay. Different ligands can be presented as discrete bands on a PVDF 
membrane and cells expressing E-selectin will be flowed on top of the membrane. The 
rolling of the cells and its engagement with particular ligands can be monitored by a light 
microscope coupled to a CCD camera. 
 
It is an interesting observation that a large cohort of potential ligands was detected 
from the MS analysis of E-selectin IP. If they are indeed E-selectin ligands (to be 
validated by functional assays), the significance of having so many E-selectin ligands 
may be explained by two models: in the first model, these membrane proteins may work 
independently to direct homing to different locations based on their 
expressions/modifications. Some selectin ligands are known to use different strategies to 
enhance their selectivity and affinity to the P-, E-, or L-selectins. For example, PSGL-1 
binds in high affinity to P-selectin when it contains tyrosine sulfation near its O-linked 
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sLeX. Similarly, L-selectin ligand binding requires sulfation on the 6-hydroxyl of the 
sLeX (Nimrichter et al., 2008). The E-selectin ligands discovered in this study may 
function as versatile homing receptors depending on the cell type in which they are 
expressed and the presence of the appropriate enzymes (i.e. glycosyltransferases and 
sulfotransferases) for specific modifications. This model warrants the further 
characterizations of the modifications required for E-selectin recognition.   
In the second model, besides facilitating cell adhesion, these membrane proteins 
might have important roles in coordinating other cellular functions after they interact with 
E-selectin. In mouse neutrophils, it was found that the activation of an E-selectin ligand, 
CD44, induces the redistribution and clustering of other adhesion molecules (e.g., L 
selectin and PSGL-1) via p38 mitogen activated protein kinase (MAPK) signaling 
(Hidalgo et al., 2007). This leads to polarization of the neutrophils and their transition 
from the initial tethering to steady slow rolling on inflamed venules. In the case of our 
study, the existence of many E-selectin ligands likely acts as switches to trigger different 
downstream signaling pathways for HSPCs homing and maintenance (i.e. proliferation, 
differentiation, cytokine production). It is interesting to further investigate whether CD34, 
a potential E-selectin ligand that emerged from our MS analysis and a known 
hematopoietic stem cell marker, mediates signaling for HSPCs self-renewal upon 
engagement with E-selectin. 
Improved understanding of E-selectin and its ligands will catalyze the 
development of therapies to facilitate stem cell delivery for clinical purposes.  For 
example, the discovery of HCELL as a potent ligand for E-selectin has inspired the 
development of a novel glycan engineering technology (Sackstein et al., 2008).  By 
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engineering the appropriate sugar modification onto mesenchymal stem cells (MSCs), 
researchers were able to convert the standard CD44 into its glycoform HCELL.  When 
these HCELL
+
 MSCs were injected into NOD/SCID mice, they successfully infiltrated 
into the bone marrow (which constitutively expresses E-selectin) within hours of 
infusion.  This is in contrast to the use the normal MSCs.  Since normal cells do not home 
well to the marrow, the fraction of osteoblasts derived from these MSCs has never 
exceeded 2%. This glycan engineering technology has profound implication in 
optimizing the MSCs transplant for patients with osteogenesis imperfecta (fragile bone). 
Thus, knowledge of the E-selectin receptor/ligand can be readily adopted in tissue 
engineering to create a "roadmap" for cell migration.  
 In summary, this study utilized mass spectrometry to comprehensively analyze 
the E-selectin ligands expressed on HSPCs. The dataset provides a useful resource to 
further characterize and narrow down the ligands critical for HSPCs tethering and 
homing. Knowledge of these ligands will expand our capacity to custom modify HSPCs 
to enhance their delivery during transplantation. In addition, through the novel glycan 
engineering technology, relevant glycoforms of these ligands can be enforced onto their 
native counterpart on any stem cell of interest. By refining the capability to direct cell 
migration towards the requisite sites, the findings from this study provide the opportunity 
to tackle challenging questions facing the current use of stem cell-based regenerative 
medicine. 
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CHAPTER II: Using Proteomics to Investigate the Molecular Mechanisms of CD44-
Ligation Induced Differentiation in Acute Myeloid Leukemia 
Chee Jia Chin 
INTRODUCTION 
 AML is a highly malignant hematopoietic tumor that affects about 13,000 adults 
in the United States each year (Ley et al., 2008). AML is characterized by a blockage of 
differentiation and uncontrolled proliferation in the hematopoietic cells during their 
development into granulocytic and monocytic lineages. According to the stage of 
differentiation blockage and blast accumulation, AML is clinically defined into different 
subtypes (1 to 7) (Charrad et al., 1999). The heterogeneous nature of AML reflects the 
fact that leukemic transformation can occur at various stages along the differentiation 
pathway (Jacobi et al., 2010) (Figure 1).  
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Figure 1. The formation of various blood lineages originates from the hematopoietic 
stem cells (HSCs). AML is the result of uncontrolled clonal proliferation in the erythroid, 
monocyte and granulocyte lineages and their precursors, originating from HSCs of the 
bone marrow. 
 
 The leukemic stem cells (LSCs) are the only cell type that is capable of initiating 
and maintaining the leukemic clonal hierarchy. In other words, they possess self-renewal 
ability and can repopulate into leukemic progenitors. LSCs residing within the tumor are 
thought to be the culprit that sustains leukemia after chemotherapy because they can give 
rise to leukemic blasts that are blocked in differentiation. These malignant leukemic 
blasts dominate the bone marrow niche and interfere with normal hematopoiesis. LSCs‟ 
slow dividing rate makes them resistant to chemotherapy drugs, which deliver 
cytotoxicity in a cell-cycle dependent fashion. The high relapse rate post chemotherapy is 
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partly attributed to the inefficient elimination of LSCs in the bone marrow. Because LSCs 
have similar cell surface profiles with the normal HSCs, which are CD34
+ 
and CD38
-
, 
decades of effort have gone into identifying antigens that are differentially expressed 
between leukemic and normal stem cell populations to selectively target and kill LSCs. 
 Many investigations have gone into developing therapeutics that can overcome 
the differentiation block in leukemia. Differentiation therapy has raised great interest due 
to the successful application of retinoic acid (RA) in treating with acute promyelocytic 
leukemia (AML3). RA treatment has proven to induce remission in greater than 90% of 
the AML3 patients (Chen et al., 1991). However, this differentiation agent is ineffective 
in other AML subtypes, which are the most frequent ones. In search for therapeutic 
targets that can inhibit proliferation of LSCs and induce differentiation of leukemic 
blasts, CD44, a surface antigen that is overexpressed on leukemic cells, emerged as a 
potential target. CD44 is a glycoprotein receptor involved in multiple cellular functions, 
including myeloid differentiation. In vitro ligation of CD44 by a specific monoclonal 
antibody (mAb), or the use of hyaluronan, its natural ligand, was able to reverse the 
differentiation block of AML blasts in all AML subtypes (Charrad et al., 1999) (Charrad 
et al., 2002) (Figure 2). The effect of targeting CD44 was further confirmed by in vivo 
study where this antibody was administrated to nonobese diabetic-severe combined 
immune-deficient (NOD-SCID) mice transplanted with human AML cells (Jin et al., 
2006). There was a 90% decrease in the engraftment of CD34
+
CD38
- 
AML LSCs to the 
BM. Moreover, these cells were unable to repopulate in secondary recipients upon serial 
transplantation, which demonstrated that the LSCs were directly targeted. Importantly, 
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the use of anti-CD44 treatment had no effect on normal HSCs, indicating a selective 
targeting of the leukemic stem cell population (Smadja-Joffe et al., 2009).  
 The in vitro and in vivo studies raised promising leads about the use of anti-CD44 
mAb in cancer therapy to reverse the leukemic phenotype. However, due to the 
ubiquitous expression of CD44, it is necessary to further narrow down a target in LSCs 
that can drive differentiation, possibly by searching through the signaling proteins 
downstream of CD44 activation (Figure 2). The downstream signaling pathways 
following CD44 activation are largely unknown and may represent the key to design 
more specific cancer therapy for eradicating leukemia. Signaling pathways depicted in 
Figure 2 are hypothetical and serve to depict the complexity of the molecular effectors 
involved in relaying the signals to drive eventually differentiation. 
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Figure 2. Targeting CD44 as a therapy for leukemia. A mAb that mediates ligation of 
CD44 has been shown to trigger differentiation in leukemic blasts from all AML 
subtypes.   
 
 Understanding the posttranslational modifications (PTM), especially the 
reversible protein phosphorylation, is important in mapping the molecular mechanisms 
responsible for CD44 induced differentiation/inhibition of proliferation in AML blasts. 
Many changes in cellular responses are orchestrated by PTM rather than triggered by 
transcriptional changes (Olsen et al., 2006). In other words, protein modifications can 
affect enzymatic activity, alter protein conformation and control where proteins reside 
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without detectable changes at the mRNA level. Another common theme that emerges 
from signaling research is that a particular protein can possess multiple phosphorylation 
sites and the phosphorylation status of these sites seems to be independent of each other. 
Depending on which sites are activated/deactivated, different downstream effectors may 
be triggered. Therefore, protein phosphorylation should be characterized "site 
specifically" rather than "grossly measured" on the entire protein. Conventional methods 
of studying signaling pathways use either western blotting analysis to characterize 
specific proteins or microarray to measure the effects of network perturbations at the 
level of the transcriptome, neither of which could examine post translational changes 
globally and comprehensively. 
 The aim of this study is to make use of state-of-the-art phosphoproteomics 
technology to visualize changes in overall phosphorylation signatures of AML cells in 
response to differentiation. MS-based proteomics has become a powerful tool to analyze 
global phosphorylation in an unbiased fashion. MS can directly quantify the effects of 
network perturbation at two different levels, the first being at the level of early 
information processing, as reflected by changes in phosphorylation levels; the second 
being at the end of the signaling cascades, where signaling output is represented by 
changes in protein abundance. The success of several large scale phophoproteomics 
projects has demonstrated the feasibility of using MS to study the temporal dynamics of 
the entire signaling pathways (Olsen et al., 2006; Van Hoof et al., 2009).  
 In this study, Stable Isotope Labeling by Amino acids in Cell culture (SILAC) is 
used to differentially label control and differentiated cells. This technique utilizes MS to 
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detect quantitative differences in protein levels between samples (Figure 3). Two cell 
populations are grown in identical medium containing either stable light or heavy 
isotopes amino acids. After a certain number of doublings, the isotope-labeled amino 
acids are metabolically incorporated into every protein of the cell. Upon differentiation 
treatment in the heavy-labeled cell population, equal amounts of cells from the two 
populations are combined, followed by standard procedures for sample preparation for 
MS analysis. The metabolic incorporation of isotope-labeled amino acids leads to a mass 
shift in the corresponding peptides, with the ratio of the peak intensities reflecting the 
relative protein amount. This differential peak intensity provides wealth of information 
indicating changes in protein expression associated with differentiation and modulation 
of phosphorylations levels in the underlying signaling pathways. To validate that the 
differential protein expressions are due to the differentiation treatment and not the use of 
heavy isotopes, reciprocal labeling experiment will be carried out where the light-labeled 
cells are treated while the heavy-labeled cells serve as control.  
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Figure 3. Experimental outline for SILAC-based phophoproteomics. (1) AML cell lines 
(HL60) are cultured in either light or heavy amino acid for 6 passages to allow full 
incorporation of the isotopes. (2) Anti-CD44 (or HA) treatment is applied to the heavy-
labeled cells and harvested at various time points. (3) The treated heavy labeled cells are 
mixed 1:1 in cell number to the control, light-labeled cells. (4) The mixed lysate are 
process with SDS-PAGE and the resulting gel lane is equally sliced into 15-20 pieces to 
extract protein from them. (5) Prior to MS analysis, the extracted proteins need to go 
through multiple phosphopeptide enrichment steps. This step is especially crucial for 
achieving comprehensive and unambiguous detection of phosphopeptides. (6) The ratio 
of peak intensities coming from the light and heavy-labeled peptides is used to deduce 
differential protein expression and post-translational modifications. 
 
 This study will allow us to fully elucidate the downstream signaling pathways 
following CD44 activation. By mapping the signaling perturbations unique to AML cells, 
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we anticipate that the results will reveal pathways responsible for blockage of 
differentiation and bring forth new therapeutic candidates for a targeted therapy for 
AML. 
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MATERIALS AND METHODS 
Cell Culture, SILAC Labeling and Phosphopeptides Enrichment 
 5x10
6
 HL60 cells (ATCC, Manassas, VA) were cultured in 25ml of SILAC 
medium (RPMI 1640 basal media) supplemented by dialyzed fetal bovine serum and 
regular L-arginine and L-lysine (Invitrogen). A second identical set of HL60 were 
cultured in L-arginine and L-lysine-U-
13
C6. After 6 doubling time (~15 days), the heavy 
lysine labeled cells were treated with anti CD44 or HA. The cells were then harvested at 
0 min, 5 min, and 15 min after treatment.  
The cells were mixed in 1:1 ratio of the untreated and light labeled cells, 
centrifuged and lysed in SILAC
TM
 Phosphoprotein Lysis Buffer B. Detailed procedures 
were followed essentially  as described in protocol from the SILAC
TM
 Protein 
Identification (ID) and Quantification Kits (Invitrogen). In-gel  protein digestion was 
performed and phosphopetides were enriched using the PiMAC
TM
 column provided in 
the kit. 
Flow Cytometry 
 CD44 or HA treated HL60 were examined day 4-post differentiation for CD11b 
and CD15 expression. The following antibodies were purchased from MACs: CD11b-
FITC (Isotype: IgG2b rat), CD15-FITC (Isotype: Mouse IgM), isotype control mouse 
IgM-FITC and isotype control rat-IgG2b. 
 Aliquots of cells (1 X 10
5
 cells) were washed with phosphate buffer saline (PBS) 
(10 mM phosphate, 150 mM sodium chloride, pH 7.2 from Invitrogen) and stained using 
primary mAbs or isotype control mAbs directly conjugated to FITC. The cells were 
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washed three times in PBS prior to fluorescence intensity determination using a BD 
FACS Canto
TM
 II (BD Biosciences). 
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RESULTS 
Analysis of differentiation after 4 days of treatment  
In order to confirm the induction of differentiation by our treatment, the 
expression of markers of differentiation has been quantified using flow cytometry. The 
human myeloid leukemia cell line (HL-60) was used to model for AML and myeloid 
differentiation. Differentiation was examined by following the expression CD11b and 
CD15.  
CD11b is a heterodimeric integral membrane proteins expressed at low levels by 
myeloblasts. As cells undergo monocytic and granulocytic differentiation, the cell surface 
expression of CD11b is expected to increase. As shown from the FACS analysis, the 
amount of cells expressing CD11b increased from 14.55% to 27.45% after 4 days of 
treatment. CD15 is a glycan determinant also known as Lewis x. It is a distinguishing 
marker for human myeloid cells. As shown by FACS (Figure 4), 98% of cells were 
already positive for CD15 prior to differentiation treatment. However, the mean 
florescent intensity of CD15 expression has increased 1.5 fold after 4 days of 
differentiation, showing that the amount of CD15 cluster within one cell increased after 
treatment. Analysis of CD11b and CD15 markers confirmed the treatment has driven 
myeloid differentiation on HL60 cell.  
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Figure 4. Examination of differentiation markers using flow cytometry. Increased CD11b 
and CD15 expression was detected on HL60 day after 4 days of treatment, confirming 
that myeloid differentiation has occurred. 
 
Greater that 99% heavy lysine incorporation efficiency was achieved  
The efficiency of heavy amino acid incorporation was determined prior to 
analyzing differential protein level between control and treated cells. This analysis will 
allow us to examine whether there is residual unlabeled peptide within the heavy lysine-
cultured cells. A subset of peptides from the heavy lysine labeled cells was analyzed. 
Only 1 peptide out of the 411 analyzed showed an unlabeled lysine residue. This 
indicated that a 99.76% labeling efficiency was achieved (Figure 5).  
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Trypsin was used to digest proteins into peptides during MS sample preparation. 
This enzyme cleaves protein after a lysine or an arginine. Since heavy lysine was used in 
cell culture, only peptides ending with lysine are informative for protein level 
determination. In the peptide characterization statistics, it was noted that 411 of the 
peptides (about 50% of total) has end cleavage at lysine and thus half of the peptides 
generated is useful for protein quantification (Table 1). Interestingly, 8.7% (33 out of 
410) of the arginine-ending peptides contained the heavy arginine isotopes, even though 
no heavy arginine was supplied to the cell culture. This finding suggested potential 
contamination from the stock of heavy lysine isoptope. 
In conclusion, greater than 99% of the peptides ending with lysine have been 
labeled with the heavy isotope. This high efficiency of incorporation will ensure 
confident interpretation of the results in subsequent analysis.  
52 
 
 
Figure 5. Characterization of heavy lysine incorporation and peptide composition 
resulting from trypsin cleavage. Among a subset of peptides examined from the heavy 
lysine cultured cells, only 1 out of 410 of lysine ending peptide did not incorporate any 
heavy lysine.  
 
Table 1. Summary statistics of mass spectrometry analysis on a subset of peptides from 
the heavy lysine-labeled cells 
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Summary statistics 
Unlabeled lysine 1 
Labeled  lysine 410 
Unlabeled arginine 377 
Labeled  arginine 33 
Odd peptide (not ending with  arginine or  lysine) 3 
Total peptides examined 824 
Efficiency of heavy  lysine incorporation (%) 99.756691 
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Loading control with equal mixing of light and heavy labeled cells indicated a systematic 
20% error rate 
In order to detect the quantification error due to unequal sample preparation, 
preliminary experiment was carried out to analyze 1:1 mixed light and heavy cells 
without treatment. Theoretically, identical peak intensity should be detected between 
each pair of light and heavy labeled peptides. Instead, a systematic 20% decrease in the 
level of heavy-labeled peptide was observed from the MS analysis (Figure 6). This error 
will be integrated as a correction factor when analysis of the mixed control and treated 
cells is carried out in future. 
54 
 
Figure 6. Analysis of equally mixed light and heavy lysine-labeled cells revealed 
systematic 20% decrease in heavy-labeled peptides. Shown here are spectra of two 
peptides pairs for illustration of the observed systematic error. Arrows point to peaks 
from corresponding pairs of peptides. This loading control experiment was performed by 
mixing 1:1 light and heavy-labeled cells without treatment. In the first spectra (top), the 
heavy labeled peptide (m/z=544.29) had a relative abundance of 74% compared to the 
light labeled peptide (m/z=541.28). In the second spectra (bottom), the heavy labeled 
peptide (m/z=572.29) had a relative abundance of 82% compared to the light labeled 
peptide (m/z=569.28). These spectra revealed an approximately 20% decrease in the level 
of heavy-labeled peptides. 
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SUMMARY 
This study aims to use quantitative proteomics to dissect the changes underlying 
CD44 activation on the entire cellular network of signal transduction. SILAC-based MS 
is used to study early phosphorylation and dephosphorylation events in AML cells upon 
differentiation. Preliminary results showed that the treatment has driven myeloid 
differentiation as demonstrated by increased CD11b and CD15 expression examined on 
day 4 after treatment. After culturing of the cells in light and heavy media we observed 
that greater than 99% incorporation efficiency was achieved using the heavy lysine 
isotope. A control experiment where light and heavy-labeled cells were equally mixed 
showed  a systematic 20% decrease in the levels of heavy-labeled proteins. 
The systematic decrease in the level of heavy-labeled proteins might be due to 
procedural errors during lysing and mixing the cells. For subsequent experiments, protein 
concentration from the lysate of light and heavy-labeled cells will be separately measured 
prior to mixing. This will allow the calibration of the differences in cell numbers that 
happened during cell harvesting. 
Although the efficiency of heavy lysine incorporation was greater than 99%, half 
of the peptides were unlabeled due to the fact that these peptides were cleaved after an 
ariginine instead of a lysine residue. The enzymatic specificity of trypsin allows it to 
cleave at lysine residue with a 50% chance, with the rest of the cleavages occurring at the 
arginine residues. Statistical analysis obtained from heavy labeled peptides confirmed 
this result as 410 peptides ended at arginine and 411 peptides ended at lysine. Peptides 
ending with an arginine will not be labeled and thus cannot be used for quantification 
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purpose to infer differential protein expression. To create a complete coverage of labeled 
peptides, heavy labeled arginine can be added alongside with heavy labeled lysine into 
the media. Another way is to substitute trypsin with an endoproteinase, Lys-C, that 
hydrolyzes specifically after a lysine residue. 
It must be acknowledged that the proteome is vastly complex and that the level of 
phosphoproteins can fluctuate at a large dynamic range. On one hand, the ability to detect 
and confidently identify phosphoproteins largely depends on the efficiency of 
phosphopeptide enrichment. On the other hand, accurately assigning PTM to the correct 
amino acid is determined by implementation of the appropriate bioinformatics pipeline. 
Some challenges anticipated in future experiments will be discussed below, including 
challenges in phosphopepetide enrichments and in the bioinformatics analysis of MS 
data.  
Phosphorylated proteins play critical role in impacting signaling pathways and 
affecting cell fates, but they tend to be less-abundant proteins, representing only 1-10% 
of the total proteome. Furthermore, most phosphoproteins have 1 to 20 sites that are 
prone to be phosphorylated (McNulty and Annan, 2009). These compounding facts 
necessitate the need of multiple phophoprotein enrichment steps prior to MS analysis. 
Otherwise, signals from phosphopeptides will be obscured from overwhelming 
background signals generated from non-phosphorylated proteins.  
In this preliminary study, Immobilized Metal Affinity Chromatography (IMAC) 
was used as a single step enrichment strategy prior to MS analysis. Few phophopeptides 
was identified from the whole proteome analysis (results not shown). Besides pulling 
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down phosphopeptides, IMAC resins are known to have a very high affinity for acidic 
peptides (containing aspartic acid and glutamic acid) and peptides containing histidine. 
Thus, by using IMAC alone, phosphopeptides enrichment is compromised by the co-
elution of highly acidic peptides. To yield a more complete set of phosphoproteins, the 
peptides can go through a fractionation step based on their electrostatic properties before 
they undergo affinity enrichment. Previous studies suggested using a hydrophilic 
interaction chromatography (HILIC) prior to IMAC to efficiently fractionate the 
phosphopeptides against the non-phosphorylated one. The highly acidic peptides were 
successfully eliminated through HILIC. Consequently, greater than 95% of the peptides 
eluted from IMAC were found to be the desired products, which were the 
phosphopeptides (McNulty and Annan, 2009).  
After obtaining the MS raw data, the next challenge lies in using bioinformatics to 
identify all possible phosphorylated peptides and to assign phosphorylation sites. Once 
sufficient number of phosphopeptides is identified (~5000 phosphopeptides is expected), 
a bioinformatics pipeline will be implemented to generate PTM score. PTM score is a 
probability based scoring system for phosphorylation site assignment within peptide 
sequences. The software accesses the probability of phosphorylation on each amino acid 
residue of the identified peptide and verifies if the surrounding sequence of a proposed 
phosphorylation site matches with known kinase motifs.  
After the phoshorylation sites are identified, several clustering programs will be 
used to describe the patterns of phosphorylation regulation and to map the network of 
kinase–substrate interactions, with the ultimate goal of determining the crucial points in 
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signal integration (Choudhary and Mann, 2010). Other typical analyses include gene 
ontology enrichment, which checks for co-regulation of proteins that are known to be 
associated with particular cellular compartments. 
Many optimizations steps lie ahead to bring this phosphoproteomics projects to its 
completion. The effort is highly justified because the success of CD44 mAb in 
eradicating acute myeloid leukemic stem cells has been discovered a decade ago but the 
signaling pathways underlying CD44 activation remain elusive to date. The identification 
of proteins perturbed by CD44 treatment will set the stage for understanding the 
biological pathways affected by CD44 activation and for designing more appropriate 
differentiation therapy for AML. This research will provide a high resolution and 
quantitative screen for molecular effectors that play major role in blocking differentiation 
and inducing abnormal proliferation. Understanding of these crucial signaling pathways 
will shed light on the therapeutic strategies for other malignant tumors that are 
maintained by cancer stem cells as well. 
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APPENDICES 
Complete dataset of mass spectrometry analysis on E-selectin IP products 
Type of search : MS/MS Ion Search  
Enzyme : Trypsin  
Variable modifications : Carbamidomethyl (C), Oxidation (M)  
Mass values : Monoisotopic  
Protein mass : Unrestricted  
Peptide mass tolerance : ± 10 ppm  
Fragment mass tolerance : ± 0.6 Da  
Max missed cleavages : 1  
Instrument type : LTQ Orbitrap  
Significance threshold p<0.01 (unless otherwise noted) 
*Note:  
 IP_RS_Eig refers to proteins from the E-selectin IP samples from the KG1a cell   
line. Likewise, IP_BM_Eig refers to samples from the bone marrow CD34
+
 cells. 
 The following class of proteins (potential contaminants) were filtered away:  
o keratin 
o hornerin 
o cytoskeletal proteins (actin, tubulin) 
o mitochondrial proteins 
o ribosomal proteins 
o histones 
 The known E-selectin ligands were highlighted. 
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IP_RS_Eig 
1 
Erythrocyte band 7 integral membrane protein OS=Homo sapiens GN=STOM 
PE=1 SV=3 
2 
Calnexin OS=Homo sapiens GN=CANX PE=1 SV=2,Calnexin OS=Pongo abelii 
GN=CANX PE=2 SV=2 
3 
Ras-related protein Rab-1A OS=Homo sapiens GN=RAB1A PE=1 SV=3,Ras-
related protein Rab-1A OS=Mus musculus GN=Rab1A PE=1 SV=3,Ras-related 
protein Rab-1A OS=Canis familiaris GN=RAB1A PE=1 SV=3,Ras-related 
protein Rab-1A OS=Sus scrofa GN=RAB1A PE=2 SV=3,Ras-related protein 
Rab-1A OS=Rattus norvegicus GN=Rab1A PE=1 SV=3 
4 
Prohibitin OS=Homo sapiens GN=PHB PE=1 SV=1,Prohibitin OS=Bos taurus 
GN=PHB PE=2 SV=1 
5 
Prohibitin-2 OS=Mus musculus GN=Phb2 PE=1 SV=1,Prohibitin-2 OS=Pongo 
abelii GN=PHB2 PE=2 SV=1,Prohibitin-2 OS=Rattus norvegicus GN=Phb2 
PE=1 SV=1,Prohibitin-2 OS=Homo sapiens GN=PHB2 PE=1 SV=2 
6 
Ras-related protein Rab-5C OS=Homo sapiens GN=RAB5C PE=1 SV=2,Ras-
related protein Rab-5C OS=Pongo abelii GN=RAB5C PE=2 SV=1 
7 
Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2,Galectin-1 OS=Rattus 
norvegicus GN=Lgals1 PE=1 SV=2,Galectin-1 OS=Cricetulus griseus 
GN=LGALS1 PE=1 SV=2,Galectin-1 OS=Pongo abelii GN=LGALS1 PE=2 
SV=3 
8 
ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 
SV=6,ADP/ATP translocase 3 OS=Bos taurus GN=SLC25A6 PE=2 
SV=3,ADP/ATP translocase 2 OS=Mus musculus GN=Slc25a5 PE=1 
SV=3,ADP/ATP translocase 2 OS=Tachyglossus aculeatus aculeatus 
GN=SLC25A5 PE=2 SV=1,ADP/ATP translocase 2 OS=Rattus norvegicus 
GN=Slc25a5 PE=1 SV=3,ADP/ATP translocase 2 OS=Bos taurus GN=SLC25A5 
PE=2 SV=3 
9 CD44 antigen OS=Homo sapiens GN=CD44 PE=1 SV=2 
10 
Heterogeneous nuclear ribonucleoprotein A1 OS=Pan troglodytes 
GN=HNRNPA1 PE=2 SV=1,Heterogeneous nuclear ribonucleoprotein A1 
OS=Rattus norvegicus GN=Hnrnpa1 PE=1 SV=3,Heterogeneous nuclear 
ribonucleoprotein A1 OS=Homo sapiens GN=HNRNPA1 PE=1 
SV=5,Heterogeneous nuclear ribonucleoprotein A1 OS=Bos taurus 
GN=HNRNPA1 PE=1 SV=2,Putative heterogeneous nuclear ribonucleoprotein 
A1-like 3 OS=Homo sapiens GN=HNRPA1L3 PE=5 SV=1,Heterogeneous 
nuclear ribonucleoprotein A1 OS=Mus musculus GN=Hnrnpa1 PE=1 
SV=2,Heterogeneous nuclear ribonucleoprotein A1 OS=Macaca mulatta 
GN=HNRNPA1 PE=2 SV=3,Heterogeneous nuclear ribonucleoprotein A1-like 2 
OS=Homo sapiens GN=HNRNPA1L2 PE=2 SV=2 
11 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 
12 Intercellular adhesion molecule 3 OS=Homo sapiens GN=ICAM3 PE=1 SV=2 
13 Hematopoietic progenitor cell antigen CD34 OS=Homo sapiens GN=CD34 PE=1 
64 
 
SV=2 
14 Sideroflexin-1 OS=Homo sapiens GN=SFXN1 PE=1 SV=4 
15 UPF0498 protein KIAA1191 homolog OS=Pongo abelii PE=2 SV=1 
16 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 
OS=Homo sapiens GN=RPN1 PE=1 SV=1,Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 1 OS=Pongo abelii GN=RPN1 PE=2 SV=1 
17 
4F2 cell-surface antigen heavy chain OS=Homo sapiens GN=SLC3A2 PE=1 
SV=3 
18 
Voltage-dependent anion-selective channel protein 3 OS=Sus scrofa 
GN=VDAC3 PE=2 SV=2,Voltage-dependent anion-selective channel protein 3 
OS=Pongo abelii GN=VDAC3 PE=2 SV=1,Voltage-dependent anion-selective 
channel protein 3 OS=Mus musculus GN=Vdac3 PE=1 SV=1,Voltage-dependent 
anion-selective channel protein 3 OS=Bos taurus GN=VDAC3 PE=2 
SV=1,Voltage-dependent anion-selective channel protein 3 OS=Oryctolagus 
cuniculus GN=VDAC3 PE=2 SV=1,Voltage-dependent anion-selective channel 
protein 3 OS=Homo sapiens GN=VDAC3 PE=1 SV=1 
19 Putative uncharacterized protein LOC100130201 OS=Homo sapiens PE=5 SV=1 
20 
HLA class I histocompatibility antigen, alpha chain G OS=Homo sapiens 
GN=HLA-G PE=1 SV=1 
21 Olfactory receptor 6C65 OS=Homo sapiens GN=OR6C65 PE=2 SV=1 
22 Endoglin OS=Homo sapiens GN=ENG PE=1 SV=2 
23 
Receptor-type tyrosine-protein phosphatase C OS=Homo sapiens GN=PTPRC 
PE=1 SV=2 
24 
Serine/threonine-protein kinase 11 OS=Gallus gallus GN=STK11 PE=2 
SV=1,Serine/threonine-protein kinase 11 OS=Homo sapiens GN=STK11 PE=1 
SV=1 
25 
Endoplasmin (Fragment) OS=Oryctolagus cuniculus GN=HSP90B1 PE=2 
SV=1,Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1,Endoplasmin 
OS=Macaca fascicularis GN=HSP90B1 PE=2 SV=1,Endoplasmin OS=Pongo 
abelii GN=HSP90B1 PE=2 SV=1 
26 
Voltage-dependent anion-selective channel protein 2 OS=Homo sapiens 
GN=VDAC2 PE=1 SV=2,Voltage-dependent anion-selective channel protein 2 
OS=Bos taurus GN=VDAC2 PE=2 SV=2,Voltage-dependent anion-selective 
channel protein 2 OS=Oryctolagus cuniculus GN=VDAC2 PE=2 SV=1,Voltage-
dependent anion-selective channel protein 2 OS=Rattus norvegicus GN=Vdac2 
PE=1 SV=2,Voltage-dependent anion-selective channel protein 2 OS=Mus 
musculus GN=Vdac2 PE=1 SV=2,Voltage-dependent anion-selective channel 
protein 2 OS=Sus scrofa GN=VDAC2 PE=2 SV=1 
27 
Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH 
PE=1 SV=3,Glyceraldehyde-3-phosphate dehydrogenase OS=Pongo abelii 
GN=GAPDH PE=2 SV=3 
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28 
Translocon-associated protein subunit delta OS=Homo sapiens GN=SSR4 PE=1 
SV=1,Translocon-associated protein subunit delta OS=Rattus norvegicus 
GN=Ssr4 PE=2 SV=1,Translocon-associated protein subunit delta OS=Bos 
taurus GN=SSR4 PE=2 SV=1,Translocon-associated protein subunit delta 
OS=Pongo abelii GN=SSR4 PE=2 SV=2,Translocon-associated protein subunit 
delta OS=Mus musculus GN=Ssr4 PE=2 SV=1 
29 Putative UPF0607 protein ENSP00000383783 OS=Homo sapiens PE=3 SV=2 
30 
Endomucin OS=Pongo abelii GN=EMCN PE=2 SV=1,Endomucin OS=Rattus 
norvegicus GN=Emcn PE=2 SV=1,Endomucin OS=Mus musculus GN=Emcn 
PE=1 SV=1,Endomucin OS=Homo sapiens GN=EMCN PE=1 SV=2 
31 
Partitioning defective 6 homolog alpha OS=Homo sapiens GN=PARD6A PE=1 
SV=1 
32 Exostosin-like 2 OS=Homo sapiens GN=EXTL2 PE=1 SV=1 
33 
UDP-glucuronosyltransferase 1-9 OS=Homo sapiens GN=UGT1A9 PE=1 
SV=1,UDP-glucuronosyltransferase 1-6 OS=Homo sapiens GN=UGT1A6 PE=1 
SV=2,UDP-glucuronosyltransferase 1-1 OS=Homo sapiens GN=UGT1A1 PE=1 
SV=1,UDP-glucuronosyltransferase 1-4 OS=Homo sapiens GN=UGT1A4 PE=1 
SV=1,UDP-glucuronosyltransferase 1-3 OS=Homo sapiens GN=UGT1A3 PE=1 
SV=1,UDP-glucuronosyltransferase 1-5 OS=Homo sapiens GN=UGT1A5 PE=1 
SV=1,UDP-glucuronosyltransferase 1-7 OS=Homo sapiens GN=UGT1A7 PE=1 
SV=2,UDP-glucuronosyltransferase 1-10 OS=Homo sapiens GN=UGT1A10 
PE=1 SV=1,UDP-glucuronosyltransferase 1-8 OS=Homo sapiens GN=UGT1A8 
PE=1 SV=1 
34 
Uncharacterized protein C17orf39 OS=Homo sapiens GN=C17orf39 PE=2 
SV=1,Uncharacterized protein C17orf39 homolog OS=Mus musculus PE=2 
SV=1 
35 Leukosialin OS=Homo sapiens GN=SPN PE=1 SV=1 
36 
Transmembrane emp24 domain-containing protein OS=Nematostella vectensis 
GN=v1g194562 PE=3 SV=1,Suppressor/enhancer of lin-12 protein 9 
OS=Caenorhabditis elegans GN=sel-9 PE=1 SV=1,Transmembrane emp24 
domain-containing protein 2 (Fragment) OS=Cricetulus griseus GN=TMED2 
PE=1 SV=1,Transmembrane emp24 domain-containing protein 2 OS=Homo 
sapiens GN=TMED2 PE=1 SV=1,Transmembrane emp24 domain-containing 
protein 2 OS=Rattus norvegicus GN=Tmed2 PE=1 SV=1,Transmembrane emp24 
domain-containing protein 2 OS=Mus musculus GN=Tmed2 PE=1 SV=1 
37 
Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2,Nucleophosmin 
OS=Rattus norvegicus GN=Npm1 PE=1 SV=1,Nucleophosmin OS=Bos taurus 
GN=NPM1 PE=2 SV=1,Nucleophosmin OS=Mus musculus GN=Npm1 PE=1 
SV=1 
38 
Lipid phosphate phosphohydrolase 3 OS=Homo sapiens GN=PPAP2B PE=1 
SV=1,Lipid phosphate phosphohydrolase 3 OS=Rattus norvegicus GN=Ppap2b 
PE=1 SV=1,Lipid phosphate phosphohydrolase 3 OS=Mus musculus 
GN=Ppap2b PE=1 SV=1 
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39 WD repeat-containing protein 31 OS=Homo sapiens GN=WDR31 PE=2 SV=1 
40 Cytochrome c oxidase subunit 2 OS=Homo sapiens GN=MT-CO2 PE=1 SV=1 
41 
Neutral amino acid transporter B(0) OS=Homo sapiens GN=SLC1A5 PE=1 
SV=2,Neutral amino acid transporter B(0) OS=Macaca fascicularis GN=SLC1A5 
PE=2 SV=1 
42 
Protein FAM83D OS=Bos taurus GN=FAM83D PE=2 SV=1,Protein FAM83D 
OS=Homo sapiens GN=FAM83D PE=1 SV=3 
43 Kynurenine 3-monooxygenase OS=Homo sapiens GN=KMO PE=1 SV=2 
44 
Putative nuclease HARBI1 OS=Bos taurus GN=HARBI1 PE=2 SV=1,Putative 
nuclease HARBI1 OS=Homo sapiens GN=HARBI1 PE=1 SV=1 
45 
60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 
SV=2,60 kDa heat shock protein, mitochondrial OS=Cricetulus griseus 
GN=HSPD1 PE=2 SV=1,60 kDa heat shock protein, mitochondrial OS=Bos 
taurus GN=HSPD1 PE=1 SV=2,60 kDa heat shock protein, mitochondrial 
OS=Mus musculus GN=Hspd1 PE=1 SV=1,60 kDa heat shock protein, 
mitochondrial OS=Rattus norvegicus GN=Hspd1 PE=1 SV=1,60 kDa heat shock 
protein, mitochondrial OS=Pongo abelii GN=HSPD1 PE=2 SV=1,60 kDa heat 
shock protein, mitochondrial OS=Gallus gallus GN=HSPD1 PE=1 SV=1 
46 Septin-5 OS=Macaca fascicularis GN=Sept5 PE=2 SV=1 
47 
14-3-3 protein beta/alpha OS=Pongo abelii GN=YWHAB PE=3 SV=1,14-3-3 
protein theta OS=Homo sapiens GN=YWHAQ PE=1 SV=1,14-3-3 protein 
zeta/delta OS=Ovis aries GN=YWHAZ PE=1 SV=1,14-3-3 protein beta/alpha 
OS=Homo sapiens GN=YWHAB PE=1 SV=3,14-3-3 protein beta/alpha 
OS=Rattus norvegicus GN=Ywhab PE=1 SV=3,14-3-3 protein zeta/delta 
OS=Mus musculus GN=Ywhaz PE=1 SV=1,14-3-3 protein zeta/delta OS=Rattus 
norvegicus GN=Ywhaz PE=1 SV=1,14-3-3 protein zeta/delta OS=Bos taurus 
GN=YWHAZ PE=1 SV=1,14-3-3 protein zeta/delta OS=Homo sapiens 
GN=YWHAZ PE=1 SV=1,14-3-3 protein beta/alpha OS=Bos taurus 
GN=YWHAB PE=1 SV=2,14-3-3 protein beta/alpha (Fragments) OS=Ovis aries 
GN=YWHAB PE=1 SV=2,14-3-3 protein theta OS=Mus musculus GN=Ywhaq 
PE=1 SV=1,14-3-3 protein theta OS=Rattus norvegicus GN=Ywhaq PE=1 
SV=1,14-3-3 protein theta OS=Bos taurus GN=YWHAQ PE=2 SV=1,14-3-3 
protein beta/alpha OS=Macaca fascicularis GN=YWHAB PE=2 SV=3,14-3-3 
protein theta OS=Xenopus laevis GN=ywhaq PE=2 SV=2,14-3-3 protein 
beta/alpha-1 OS=Danio rerio GN=ywhab1 PE=2 SV=2,14-3-3 protein zeta/delta 
OS=Pongo abelii GN=YWHAZ PE=2 SV=1,14-3-3 protein theta OS=Pongo 
abelii GN=YWHAQ PE=2 SV=2,14-3-3 protein zeta OS=Gallus gallus 
GN=YWHAZ PE=2 SV=1,14-3-3 protein beta/alpha OS=Gallus gallus 
GN=YWHAB PE=2 SV=1,14-3-3 protein theta OS=Gallus gallus GN=YWHAQ 
PE=2 SV=1,14-3-3 protein theta OS=Oryctolagus cuniculus GN=YWHAQ PE=2 
SV=1,14-3-3 protein beta/alpha-2 OS=Oncorhynchus mykiss PE=2 SV=1,14-3-3 
protein beta/alpha OS=Mus musculus GN=Ywhab PE=1 SV=3 
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48 
Transferrin receptor protein 1 OS=Homo sapiens GN=TFRC PE=1 
SV=2,Transferrin receptor protein 1 OS=Pongo abelii GN=TFRC PE=2 SV=1 
49 
GRIP1-associated protein 1 OS=Homo sapiens GN=GRIPAP1 PE=1 
SV=1,GRIP1-associated protein 1 OS=Mus musculus GN=Gripap1 PE=1 
SV=1,GRIP1-associated protein 1 OS=Rattus norvegicus GN=Gripap1 PE=1 
SV=1 
50 
Protein Wnt-4 OS=Mus musculus GN=Wnt4 PE=1 SV=1,Protein Wnt-8 
OS=Xenopus laevis GN=wnt8 PE=1 SV=2,Protein Wnt-4a OS=Danio rerio 
GN=wnt4a PE=2 SV=1,Protein Wnt-4 OS=Gallus gallus GN=WNT4 PE=1 
SV=1,Protein Wnt-4 OS=Xenopus laevis GN=wnt4 PE=2 SV=1,Protein Wnt-4 
OS=Homo sapiens GN=WNT4 PE=1 SV=4,Protein Wnt-4 OS=Rattus 
norvegicus GN=Wnt4 PE=2 SV=1 
51 E-selectin OS=Homo sapiens GN=SELE PE=1 SV=1 
52 
Stress-70 protein, mitochondrial OS=Homo sapiens GN=HSPA9 PE=1 
SV=2,Stress-70 protein, mitochondrial OS=Bos taurus GN=HSPA9 PE=2 
SV=1,Stress-70 protein, mitochondrial OS=Pongo abelii GN=HSPA9 PE=2 
SV=1 
53 
Ankyrin repeat and LEM domain-containing protein 1 OS=Homo sapiens 
GN=ANKLE1 PE=2 SV=1 
54 
Phytanoyl-CoA hydroxylase-interacting protein OS=Bos taurus GN=PHYHIP 
PE=2 SV=1,Phytanoyl-CoA hydroxylase-interacting protein OS=Rattus 
norvegicus GN=Phyhip PE=2 SV=1,Phytanoyl-CoA hydroxylase-interacting 
protein OS=Pongo abelii GN=PHYHIP PE=2 SV=1,Phytanoyl-CoA 
hydroxylase-interacting protein OS=Mus musculus GN=Phyhip PE=1 
SV=1,Phytanoyl-CoA hydroxylase-interacting protein OS=Homo sapiens 
GN=PHYHIP PE=1 SV=1 
55 
CREB-regulated transcription coactivator 2 OS=Bos taurus GN=CRTC2 PE=2 
SV=1,CREB-regulated transcription coactivator 2 OS=Rattus norvegicus 
GN=Crtc2 PE=1 SV=1,CREB-regulated transcription coactivator 2 OS=Mus 
musculus GN=Crtc2 PE=1 SV=2,CREB-regulated transcription coactivator 2 
OS=Homo sapiens GN=CRTC2 PE=1 SV=2 
56 Zinc finger protein 395 OS=Homo sapiens GN=ZNF395 PE=1 SV=2 
57 
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex, mitochondrial OS=Homo sapiens GN=DLST PE=1 
SV=3,Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial OS=Sus scrofa GN=DLST 
PE=1 SV=1 
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58 
Alpha-actinin-4 OS=Bos taurus GN=ACTN4 PE=2 SV=1,Alpha-actinin-4 
OS=Homo sapiens GN=ACTN4 PE=1 SV=2,Alpha-actinin-1 OS=Gallus gallus 
GN=ACTN1 PE=1 SV=3,Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 
SV=2,Alpha-actinin-2 OS=Gallus gallus GN=ACTN2 PE=2 SV=1,Alpha-
actinin-2 OS=Homo sapiens GN=ACTN2 PE=1 SV=1,Alpha-actinin-4 OS=Mus 
musculus GN=Actn4 PE=1 SV=1,Alpha-actinin-1 OS=Macaca fascicularis 
GN=ACTN1 PE=2 SV=1,Alpha-actinin-1 OS=Bos taurus GN=ACTN1 PE=2 
SV=1,Alpha-actinin-2 OS=Bos taurus GN=ACTN2 PE=2 SV=1,Alpha-actinin-4 
OS=Pongo abelii GN=ACTN4 PE=2 SV=1,Alpha-actinin-4 OS=Gallus gallus 
GN=ACTN4 PE=1 SV=1,Alpha-actinin-2 OS=Mus musculus GN=Actn2 PE=1 
SV=1,Alpha-actinin-1 OS=Rattus norvegicus GN=Actn1 PE=1 SV=1 
59 
Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 
SV=4,Heat shock protein HSP 90-beta OS=Mus musculus GN=Hsp90ab1 PE=1 
SV=2,Heat shock protein HSP 90-beta OS=Rattus norvegicus GN=Hsp90ab1 
PE=1 SV=4,Heat shock cognate protein HSP 90-beta OS=Gallus gallus 
GN=HSP90AB1 PE=2 SV=1,Heat shock protein HSP 90-beta OS=Macaca 
fascicularis GN=Hsp90ab1 PE=2 SV=1,Heat shock protein HSP 90-beta 
OS=Pongo abelii GN=HSP90AB1 PE=2 SV=1,Heat shock protein HSP 90-beta 
OS=Bos taurus GN=HSP90AB1 PE=2 SV=3,Heat shock protein HSP 90-beta 
OS=Equus caballus GN=HSP90AB1 PE=2 SV=3 
60 
Proliferation-associated protein 2G4 OS=Mus musculus GN=Pa2g4 PE=1 
SV=3,Proliferation-associated protein 2G4 OS=Homo sapiens GN=PA2G4 PE=1 
SV=3 
61 
Heat shock protein HSP 90-alpha OS=Pan troglodytes GN=HSP90AA1 PE=2 
SV=1,Heat shock protein HSP 90-alpha OS=Sus scrofa GN=HSP90AA1 PE=2 
SV=3,Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 
PE=1 SV=5,Heat shock protein HSP 90-alpha OS=Mus musculus GN=Hsp90aa1 
PE=1 SV=4,Heat shock protein HSP 90-alpha OS=Gallus gallus GN=HSP90AA1 
PE=3 SV=3,Heat shock protein HSP 90-alpha OS=Rattus norvegicus 
GN=Hsp90aa1 PE=1 SV=3,Heat shock protein HSP 90-alpha OS=Macaca 
fascicularis GN=HSP90AA1 PE=2 SV=3,Heat shock protein HSP 90-alpha 
OS=Bos taurus GN=HSP90AA1 PE=2 SV=3,Heat shock protein HSP 90-alpha 
(Fragment) OS=Equus caballus GN=HSP90AA1 PE=2 SV=1 
62 Myomesin-1 OS=Homo sapiens GN=MYOM1 PE=1 SV=2 
63 
Uronyl 2-sulfotransferase OS=Mus musculus GN=Ust PE=2 SV=2,Uronyl 2-
sulfotransferase OS=Homo sapiens GN=UST PE=2 SV=1 
64 Integrin beta-2 OS=Homo sapiens GN=ITGB2 PE=1 SV=2 
65 Sodium/glucose cotransporter 1 OS=Homo sapiens GN=SLC5A1 PE=1 SV=1 
66 SH3 domain-binding protein 1 OS=Homo sapiens GN=SH3BP1 PE=1 SV=3 
67 Cell surface glycoprotein MUC18 OS=Homo sapiens GN=MCAM PE=1 SV=2 
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68 
KH domain-containing, RNA-binding, signal transduction-associated protein 2 
OS=Danio rerio GN=khdrbs2 PE=2 SV=1,KH domain-containing, RNA-binding, 
signal transduction-associated protein 2 OS=Homo sapiens GN=KHDRBS2 
PE=1 SV=1,KH domain-containing, RNA-binding, signal transduction-associated 
protein 2 OS=Rattus norvegicus GN=Khdrbs2 PE=1 SV=1,KH domain-
containing, RNA-binding, signal transduction-associated protein 2 OS=Mus 
musculus GN=Khdrbs2 PE=1 SV=1 
69 
Semenogelin-2 OS=Hylobates lar GN=SEMG2 PE=2 SV=1,Semenogelin-2 
OS=Hylobates klossii GN=SEMG2 PE=3 SV=1 
70 Zinc finger protein 74 OS=Homo sapiens GN=ZNF74 PE=2 SV=2 
71 Cytochrome P450 26B1 OS=Homo sapiens GN=CYP26B1 PE=2 SV=1 
72 
Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A 
OS=Cricetulus griseus GN=MGAT5 PE=2 SV=1,Alpha-1,6-
mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A OS=Rattus 
norvegicus GN=Mgat5 PE=1 SV=1,Alpha-1,6-mannosylglycoprotein 6-beta-N-
acetylglucosaminyltransferase A OS=Homo sapiens GN=MGAT5 PE=1 
SV=1,Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase 
A OS=Mus musculus GN=Mgat5 PE=2 SV=1 
73 
Fatty acid desaturase 1 OS=Homo sapiens GN=FADS1 PE=1 SV=1,Fatty acid 
desaturase 1 OS=Mus musculus GN=Fads1 PE=2 SV=1,Fatty acid desaturase 1 
OS=Rattus norvegicus GN=Fads1 PE=2 SV=1 
74 P-selectin glycoprotein ligand 1 OS=Homo sapiens GN=SELPLG PE=1 SV=1 
75 
Moesin OS=Rattus norvegicus GN=Msn PE=1 SV=3,Ezrin OS=Homo sapiens 
GN=EZR PE=1 SV=4,Moesin OS=Homo sapiens GN=MSN PE=1 SV=3,Ezrin 
OS=Mus musculus GN=Ezr PE=1 SV=3,Moesin OS=Mus musculus GN=Msn 
PE=1 SV=3,Moesin OS=Sus scrofa GN=MSN PE=2 SV=3,Radixin OS=Mus 
musculus GN=Rdx PE=1 SV=2,Radixin OS=Sus scrofa GN=RDX PE=2 
SV=1,Ezrin OS=Bos taurus GN=EZR PE=1 SV=2,Ezrin OS=Rattus norvegicus 
GN=Ezr PE=1 SV=3,Radixin OS=Homo sapiens GN=RDX PE=1 SV=1,Moesin 
OS=Lytechinus variegatus PE=3 SV=1,Moesin OS=Bos taurus GN=MSN PE=2 
SV=3,Radixin OS=Bos taurus GN=RDX PE=2 SV=1,Ezrin OS=Oryctolagus 
cuniculus GN=EZR PE=1 SV=3,Radixin OS=Gallus gallus GN=RDX PE=2 
SV=1 
76 
E3 ubiquitin-protein ligase Praja-2 OS=Homo sapiens GN=PJA2 PE=1 SV=4,E3 
ubiquitin-protein ligase Praja-2 OS=Pongo abelii GN=PJA2 PE=2 SV=1,E3 
ubiquitin-protein ligase Praja-2 OS=Mus musculus GN=Pja2 PE=1 SV=2 
77 
Bardet-Biedl syndrome 12 protein homolog OS=Pongo abelii GN=BBS12 PE=2 
SV=2,Bardet-Biedl syndrome 12 protein OS=Homo sapiens GN=BBS12 PE=1 
SV=1 
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78 
HERV-K_19q12 provirus ancestral Env polyprotein OS=Homo sapiens PE=1 
SV=2,HERV-K_5q33.3 provirus ancestral Env polyprotein OS=Homo sapiens 
PE=1 SV=2,HERV-K_22q11.21 provirus ancestral Env polyprotein OS=Homo 
sapiens PE=2 SV=1,HERV-K_1q22 provirus ancestral Env polyprotein 
OS=Homo sapiens PE=2 SV=1,HERV-K_1q22 provirus ancestral Pol protein 
OS=Homo sapiens PE=3 SV=1,HERV-K_7p22.1 provirus ancestral Env 
polyprotein OS=Homo sapiens GN=ERVK6 PE=1 SV=1,HERV-K_8p23.1 
provirus ancestral Env polyprotein OS=Homo sapiens PE=1 SV=1,HERV-
K_6q14.1 provirus ancestral Env polyprotein OS=Homo sapiens PE=1 SV=1 
79 MAP7 domain-containing protein 2 OS=Pongo abelii GN=MAP7D2 PE=2 SV=1 
80 
T-complex protein 1 subunit epsilon OS=Homo sapiens GN=CCT5 PE=1 
SV=1,T-complex protein 1 subunit epsilon OS=Macaca fascicularis GN=CCT5 
PE=2 SV=1,T-complex protein 1 subunit epsilon OS=Pongo abelii GN=CCT5 
PE=2 SV=1,T-complex protein 1 subunit epsilon OS=Rattus norvegicus 
GN=Cct5 PE=1 SV=1 
81 
Motile sperm domain-containing protein 2 OS=Homo sapiens GN=MOSPD2 
PE=1 SV=1,Motile sperm domain-containing protein 2 OS=Mus musculus 
GN=Mospd2 PE=1 SV=2 
82 
Nuclear factor erythroid 2-related factor 3 OS=Homo sapiens GN=NFE2L3 PE=1 
SV=1 
83 Putative phospholipase B-like 1 OS=Homo sapiens GN=PLBD1 PE=1 SV=2 
84 Prolyl 3-hydroxylase 2 OS=Homo sapiens GN=LEPREL1 PE=2 SV=1 
85 
Actin-related protein 2 OS=Bos taurus GN=ACTR2 PE=1 SV=1,Actin-related 
protein 2 OS=Drosophila melanogaster GN=Arp14D PE=2 SV=2,Actin-related 
protein 2 OS=Gallus gallus GN=ACTR2 PE=2 SV=1,Actin-related protein 2 
OS=Caenorhabditis elegans GN=arx-2 PE=3 SV=1,Actin-related protein 2 
OS=Homo sapiens GN=ACTR2 PE=1 SV=1,Actin-related protein 2 OS=Mus 
musculus GN=Actr2 PE=1 SV=1,Actin-related protein 2-B OS=Danio rerio 
GN=actr2b PE=2 SV=1,Actin-related protein 2 OS=Xenopus tropicalis GN=actr2 
PE=2 SV=1,Actin-related protein 2 OS=Rattus norvegicus GN=Actr2 PE=2 
SV=1,Actin-related protein 2 OS=Pongo abelii GN=ACTR2 PE=2 SV=1,Actin-
related protein 2 OS=Caenorhabditis briggsae GN=arx-2 PE=3 SV=1,Actin-
related protein 2-A OS=Danio rerio GN=actr2a PE=2 SV=1,Actin-related protein 
2-A OS=Xenopus laevis GN=actr2-A PE=2 SV=1,Actin-related protein 2-B 
OS=Xenopus laevis GN=actr2-B PE=2 SV=1 
86 Uncharacterized protein C7orf63 OS=Callithrix jacchus PE=4 SV=1 
87 Mismatch repair endonuclease PMS2 OS=Homo sapiens GN=PMS2 PE=1 SV=1 
88 
Sodium/potassium-transporting ATPase subunit alpha-3 OS=Rattus norvegicus 
GN=Atp1a3 PE=1 SV=2,Sodium/potassium-transporting ATPase subunit alpha-3 
OS=Homo sapiens GN=ATP1A3 PE=1 SV=3,Sodium/potassium-transporting 
ATPase subunit alpha-3 OS=Mus musculus GN=Atp1a3 PE=1 SV=1 
89 
Protein disulfide-isomerase-like protein of the testis OS=Homo sapiens 
GN=PDILT PE=1 SV=2 
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90 
cGMP-specific 3',5'-cyclic phosphodiesterase OS=Homo sapiens GN=PDE5A 
PE=1 SV=1,cGMP-specific 3',5'-cyclic phosphodiesterase OS=Canis familiaris 
GN=PDE5A PE=2 SV=1,cGMP-specific 3',5'-cyclic phosphodiesterase OS=Bos 
taurus GN=PDE5A PE=1 SV=1 
91 FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2 
92 Myosin-XIX OS=Homo sapiens GN=MYO19 PE=2 SV=2 
93 
Mediator of RNA polymerase II transcription subunit 24 OS=Homo sapiens 
GN=MED24 PE=1 SV=1,Mediator of RNA polymerase II transcription subunit 
24 OS=Rattus norvegicus GN=Med24 PE=2 SV=1,Mediator of RNA polymerase 
II transcription subunit 24 OS=Gallus gallus GN=MED24 PE=2 SV=1,Mediator 
of RNA polymerase II transcription subunit 24 OS=Mus musculus GN=Med24 
PE=1 SV=1 
94 
Disco-interacting protein 2 homolog A OS=Homo sapiens GN=DIP2A PE=2 
SV=2 
95 Complement receptor type 1 OS=Homo sapiens GN=CR1 PE=1 SV=3 
96 Copper-transporting ATPase 1 OS=Homo sapiens GN=ATP7A PE=1 SV=3 
97 
Ubiquitin carboxyl-terminal hydrolase 37 OS=Homo sapiens GN=USP37 PE=1 
SV=1,Ubiquitin carboxyl-terminal hydrolase 37 OS=Mus musculus GN=Usp37 
PE=1 SV=1 
98 
Glutamate [NMDA] receptor subunit zeta-1 OS=Mus musculus GN=Grin1 PE=1 
SV=1,Glutamate [NMDA] receptor subunit zeta-1 OS=Rattus norvegicus 
GN=Grin1 PE=1 SV=1,Glutamate [NMDA] receptor subunit zeta-1 OS=Homo 
sapiens GN=GRIN1 PE=1 SV=1,Glutamate [NMDA] receptor subunit zeta-1 
OS=Canis familiaris GN=GRIN1 PE=2 SV=2 
99 
SWI/SNF complex subunit SMARCC2 OS=Homo sapiens GN=SMARCC2 
PE=1 SV=1 
100 Integrin alpha-L OS=Homo sapiens GN=ITGAL PE=1 SV=3 
101 
Exportin-2 OS=Bos taurus GN=CSE1L PE=2 SV=1,Exportin-2 OS=Homo 
sapiens GN=CSE1L PE=1 SV=3,Exportin-2 OS=Pongo abelii GN=CSE1L PE=2 
SV=1,Exportin-2 OS=Xenopus laevis GN=cse1l PE=2 SV=1,Exportin-2 
OS=Mus musculus GN=Cse1l PE=2 SV=1 
102 
Chromodomain-helicase-DNA-binding protein 5 OS=Homo sapiens GN=CHD5 
PE=1 SV=1 
103 
Neurogenic locus notch homolog protein 3 OS=Homo sapiens GN=NOTCH3 
PE=1 SV=1 
104 
A disintegrin and metalloproteinase with thrombospondin motifs 20 OS=Homo 
sapiens GN=ADAMTS20 PE=2 SV=2 
105 
Sodium channel protein type 3 subunit alpha OS=Homo sapiens GN=SCN3A 
PE=1 SV=2 
106 
Nipped-B-like protein OS=Homo sapiens GN=NIPBL PE=1 SV=2,Nipped-B-
like protein OS=Mus musculus GN=Nipbl PE=1 SV=1 
107 Nephrin OS=Homo sapiens GN=NPHS1 PE=1 SV=1 
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108 
Serine/threonine-protein kinase LMTK1 OS=Homo sapiens GN=AATK PE=1 
SV=2 
109 Tyrosine-protein kinase BAZ1B OS=Homo sapiens GN=BAZ1B PE=1 SV=2 
110 
Protein piccolo OS=Rattus norvegicus GN=Pclo PE=1 SV=1,Protein piccolo 
OS=Mus musculus GN=Pclo PE=1 SV=3 
111 Golgin subfamily B member 1 OS=Homo sapiens GN=GOLGB1 PE=1 SV=2 
112 PDZ domain-containing protein 2 OS=Homo sapiens GN=PDZD2 PE=1 SV=4 
113 
Sodium channel protein type 1 subunit alpha OS=Rattus norvegicus GN=Scn1a 
PE=2 SV=1,Sodium channel protein type 1 subunit alpha OS=Homo sapiens 
GN=SCN1A PE=1 SV=2 
114 
Serine/threonine-protein kinase ATR OS=Homo sapiens GN=ATR PE=1 
SV=3,Serine/threonine-protein kinase ATR OS=Mus musculus GN=Atr PE=1 
SV=2 
115 Zinc finger protein 804B OS=Homo sapiens GN=ZNF804B PE=1 SV=2 
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IP_BM_Eig  
1 
Small proline-rich protein 2B OS=Mus musculus GN=Sprr2b PE=2 SV=1,Small 
proline-rich protein 2D OS=Mus musculus GN=Sprr2d PE=2 SV=1,Small 
proline-rich protein 2G OS=Mus musculus GN=Sprr2g PE=2 SV=1,Small 
proline-rich protein 2H OS=Mus musculus GN=Sprr2h PE=2 SV=1,Small 
proline-rich protein 2K OS=Mus musculus GN=Sprr2k PE=2 SV=1,Small 
proline-rich protein 2E OS=Homo sapiens GN=SPRR2E PE=2 SV=2,Small 
proline-rich protein 2D OS=Homo sapiens GN=SPRR2D PE=2 SV=2,Small 
proline-rich protein 2B OS=Homo sapiens GN=SPRR2B PE=2 SV=1,Small 
proline-rich protein 2A OS=Homo sapiens GN=SPRR2A PE=2 SV=1,Small 
proline-rich protein 2F OS=Homo sapiens GN=SPRR2F PE=2 SV=1,Small 
proline-rich protein 2G OS=Homo sapiens GN=SPRR2G PE=2 SV=1 
2 Ig lambda chain C regions OS=Homo sapiens GN=IGLC1 PE=1 SV=1 
3 Apolipoprotein D OS=Homo sapiens GN=APOD PE=1 SV=1 
4 Annexin A6 OS=Homo sapiens GN=ANXA6 PE=1 SV=3 
5 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 
6 
Galectin-9B OS=Homo sapiens GN=LGALS9B PE=2 SV=3,Galectin-9C 
OS=Homo sapiens GN=LGALS9C PE=2 SV=1 
7 Galectin-9 OS=Homo sapiens GN=LGALS9 PE=1 SV=2 
8 
HLA class I histocompatibility antigen, A-3 alpha chain OS=Homo sapiens 
GN=HLA-A PE=1 SV=2,HLA class I histocompatibility antigen, A-24 alpha 
chain OS=Homo sapiens GN=HLA-A PE=1 SV=2,HLA class I 
histocompatibility antigen, A-11 alpha chain OS=Homo sapiens GN=HLA-A 
PE=1 SV=1,CHLA class I histocompatibility antigen, A-108 alpha chain OS=Pan 
troglodytes GN=Patr-A PE=2 SV=2,HLA class I histocompatibility antigen, A-
30 alpha chain OS=Homo sapiens GN=HLA-A PE=1 SV=2,CHLA class I 
histocompatibility antigen, A-2 alpha chain OS=Pan troglodytes PE=2 
SV=1,HLA class I histocompatibility antigen, A-23 alpha chain OS=Homo 
sapiens GN=HLA-A PE=1 SV=1 
9 Active regulator of SIRT1 OS=Homo sapiens GN=RPS19BP1 PE=1 SV=1 
10 Phospholipase D4 OS=Homo sapiens GN=PLD4 PE=1 SV=2 
11 CD44 antigen OS=Homo sapiens GN=CD44 PE=1 SV=2 
12 Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1 
13 Leukosialin OS=Homo sapiens GN=SPN PE=1 SV=1 
14 
Erythrocyte band 7 integral membrane protein OS=Homo sapiens GN=STOM 
PE=1 SV=3,Erythrocyte band 7 integral membrane protein OS=Mus musculus 
GN=Stom PE=1 SV=3 
15 Integrin beta-2 OS=Homo sapiens GN=ITGB2 PE=1 SV=2 
16 HCLS1-associated protein X-1 OS=Homo sapiens GN=HAX1 PE=1 SV=2 
17 E-selectin OS=Homo sapiens GN=SELE PE=1 SV=1 
18 
Kinesin heavy chain isoform 5C OS=Homo sapiens GN=KIF5C PE=1 
SV=1,Kinesin heavy chain isoform 5C OS=Mus musculus GN=Kif5c PE=1 
SV=2 
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19 
Golgi integral membrane protein 4 OS=Homo sapiens GN=GOLIM4 PE=1 
SV=1,Golgi integral membrane protein 4 OS=Rattus norvegicus GN=Golim4 
PE=1 SV=2,Golgi integral membrane protein 4 OS=Mus musculus GN=Golim4 
PE=1 SV=1 
20 Protein THEMIS OS=Homo sapiens GN=THEMIS PE=1 SV=3 
21 
Elongation factor 1-alpha 1 OS=Equus caballus GN=EEF1A1 PE=2 
SV=1,Elongation factor 1-alpha OS=Pichia guilliermondii GN=TEF1 PE=3 
SV=2,Elongation factor 1-alpha OS=Vicia faba PE=2 SV=1,Elongation factor 1-
alpha OS=Cryptococcus neoformans GN=TEF1 PE=2 SV=2,Elongation factor 1-
alpha OS=Schizophyllum commune GN=TEF1 PE=3 SV=1,Elongation factor 1-
alpha OS=Manihot esculenta GN=EF1 PE=3 SV=1,Elongation factor 1-alpha 
OS=Yarrowia lipolytica GN=TEF PE=2 SV=2,Elongation factor 1-alpha 
OS=Oryza sativa subsp. japonica GN=REFA1 PE=2 SV=2,Elongation factor 1-
alpha OS=Artemia salina PE=1 SV=2,Elongation factor 1-alpha 
OS=Saccharomyces cerevisiae GN=TEF1 PE=1 SV=1,Elongation factor 1-alpha 
2 OS=Drosophila melanogaster GN=Ef1alpha100E PE=1 SV=2,Elongation 
factor 1-alpha OS=Rhizomucor racemosus GN=TEF-1 PE=3 SV=1,Elongation 
factor 1-alpha 1 OS=Drosophila melanogaster GN=Ef1alpha48D PE=1 
SV=2,Elongation factor 1-alpha 1 OS=Mus musculus GN=Eef1a1 PE=1 
SV=3,Elongation factor 1-alpha, somatic form OS=Xenopus laevis GN=eef1as 
PE=2 SV=1,Elongation factor 1-alpha OS=Arabidopsis thaliana GN=A1 PE=1 
SV=1,Elongation factor 1-alpha OS=Rhizomucor racemosus GN=TEF-2 PE=3 
SV=1,Elongation factor 1-alpha OS=Rhizomucor racemosus GN=TEF-3 PE=3 
SV=1,Elongation factor 1-alpha OS=Euglena gracilis GN=TEF PE=2 
SV=1,Elongation factor 1-alpha OS=Candida albicans GN=TEF1 PE=1 
SV=1,Elongation factor 1-alpha OS=Xenopus laevis PE=1 SV=2,Elongation 
factor 1-alpha, oocyte form OS=Xenopus laevis GN=eef1ao PE=1 
SV=1,Elongation factor 1-alpha, oocyte form OS=Xenopus laevis PE=1 
SV=2,Elongation factor 1-alpha OS=Solanum lycopersicum PE=2 
SV=1,Elongation factor 1-alpha OS=Dictyostelium discoideum GN=eef1a1 PE=1 
SV=2,Elongation factor 1-alpha OS=Apis mellifera PE=3 SV=1,Elongation 
factor 1-alpha OS=Glycine max GN=TEFS1 PE=3 SV=2,Elongation factor 1-
alpha OS=Onchocerca volvulus PE=2 SV=1,Elongation factor 1-alpha 
OS=Absidia glauca GN=TEF-1 PE=3 SV=1,Elongation factor 1-alpha 
OS=Bombyx mori PE=2 SV=1,Elongation factor 1-alpha OS=Daucus carota 
PE=3 SV=1,Elongation factor 1-alpha OS=Entamoeba histolytica PE=2 
SV=1,Elongation factor 1-alpha OS=Puccinia graminis GN=TEF PE=3 
SV=2,Elongation factor 1-alpha OS=Daucus carota PE=2 SV=1,Elongation 
factor 1-alpha OS=Hordeum vulgare PE=1 SV=1,Elongation factor 1-alpha 
OS=Ajellomyces capsulata (strain ATCC 26029 / G186AR / H82 / RMSCC 
2432) GN=TEF PE=2 SV=1,Elongation factor 1-alpha OS=Arxula adeninivorans 
GN=TEF PE=3 SV=1,Elongation factor 1-alpha OS=Ashbya gossypii GN=TEF 
PE=3 SV=1,Elongation factor 1-alpha OS=Nicotiana tabacum PE=2 
SV=1,Elongation factor 1-alpha C OS=Porphyra purpurea GN=TEF-C PE=2 
SV=1,Elongation factor 1-alpha S OS=Porphyra purpurea GN=TEF-S PE=2 
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SV=1,Elongation factor 1-alpha-A OS=Schizosaccharomyces pombe GN=tef1a 
PE=1 SV=2,Elongation factor 1-alpha OS=Caenorhabditis elegans GN=eft-3 
PE=2 SV=1,Elongation factor 1-alpha 1 OS=Cricetulus griseus GN=EEF1A1 
PE=2 SV=1,Elongation factor 1-alpha 1 OS=Rattus norvegicus GN=Eef1a1 
PE=2 SV=1,Elongation factor 1-alpha 2 OS=Mus musculus GN=Eef1a2 PE=1 
SV=1,Elongation factor 1-alpha 2 OS=Rattus norvegicus GN=Eef1a2 PE=2 
SV=1,Elongation factor 1-alpha 1 OS=Bos taurus GN=EEF1A1 PE=2 
SV=1,Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 
SV=1,Elongation factor 1-alpha 1 OS=Oryctolagus cuniculus GN=EEF1A1 
PE=1 SV=1,Elongation factor 1-alpha (Fragment) OS=Heliothis virescens PE=3 
SV=1,Elongation factor 1-alpha (Fragment) OS=Heliothis zea PE=3 
SV=1,Elongation factor 1-alpha (Fragment) OS=Helicoverpa armigera PE=3 
SV=1,Elongation factor 1-alpha (Fragment) OS=Helicoverpa gelotopoeon PE=3 
SV=1,Elongation factor 1-alpha (Fragment) OS=Heliocheilus albipunctella PE=3 
SV=1,Elongation factor 1-alpha (Fragment) OS=Heliocheilus discalis PE=3 
SV=1,Elongation factor 1-alpha (Fragment) OS=Adisura bella PE=3 
SV=1,Elongation factor 1-alpha (Fragment) OS=Anicla infecta PE=3 
SV=1,Elongation factor 1-alpha OS=Cryptosporidium parvum PE=2 
SV=1,Elongation factor 1-alpha OS=Aureobasidium pullulans GN=TEF1 PE=3 
SV=1,Elongation factor 1-alpha OS=Neurospora crassa GN=tef-1 PE=3 
SV=2,Elongation factor 1-alpha OS=Podospora anserina GN=TEF PE=3 
SV=1,Elongation factor 1-alpha OS=Podospora curvicolla GN=TEF PE=3 
SV=1,Elongation factor 1-alpha OS=Triticum aestivum GN=TEF1 PE=2 
SV=1,Elongation factor 1-alpha OS=Tetrahymena pyriformis PE=2 
SV=1,Elongation factor 1-alpha 2 OS=Homo sapiens GN=EEF1A2 PE=1 
SV=1,Elongation factor 1-alpha OS=Sordaria macrospora GN=TEF PE=3 
SV=1,Elongation factor 1-alpha-B/C OS=Schizosaccharomyces pombe 
GN=tef1b PE=1 SV=1,Elongation factor 1-alpha (Fragment) OS=Spodoptera 
frugiperda PE=1 SV=1,Elongation factor 1-alpha 1 OS=Euplotes crassus 
GN=EFA1 PE=3 SV=1,Elongation factor 1-alpha 2 OS=Euplotes crassus 
GN=EFA2 PE=3 SV=1,Elongation factor 1-alpha 1 OS=Oscheius tipulae 
GN=eft-1 PE=3 SV=1,Elongation factor 1-alpha 3 OS=Oscheius tipulae GN=eft-
3 PE=3 SV=1,Elongation factor 1-alpha 2 OS=Oscheius tipulae GN=eft-2 PE=3 
SV=1,Elongation factor 1-alpha 4 OS=Oscheius tipulae GN=eft-4 PE=3 
SV=1,Elongation factor 1-alpha 2 OS=Bos taurus GN=EEF1A2 PE=2 
SV=1,Elongation factor 1-alpha OS=Hordeum vulgare GN=BLT63 PE=1 
SV=1,Elongation factor 1-alpha OS=Zea mays GN=EF1A PE=3 
SV=1,Elongation factor 1-alpha 1 OS=Pan troglodytes GN=EEF1A1 PE=2 
SV=1,Elongation factor 1-alpha 1 OS=Pongo abelii GN=EEF1A1 PE=2 
SV=2,Putative elongation factor 1-alpha-like 3 OS=Homo sapiens 
GN=EEF1AL3 PE=5 SV=1,Elongation factor 1-alpha 1 OS=Felis catus 
GN=EEF1A1 PE=2 SV=1,Elongation factor 1-alpha 2 OS=Oryctolagus 
cuniculus GN=EEF1A2 PE=1 SV=1,Elongation factor 1-alpha OS=Porphyra 
yezoensis PE=2 SV=1,Elongation factor 1-alpha 1 OS=Gallus gallus GN=EEF1A 
PE=2 SV=1,Elongation factor 1-alpha OS=Danio rerio GN=eef1a PE=2 
76 
 
SV=1,Elongation factor 1-alpha OS=Coccidioides immitis GN=TEF PE=2 
SV=2,Elongation factor 1-alpha OS=Piriformospora indica GN=TEF1 PE=2 
SV=1,Elongation factor 1-alpha OS=Aspergillus oryzae GN=tef1 PE=3 SV=1 
22 
4F2 cell-surface antigen heavy chain OS=Homo sapiens GN=SLC3A2 PE=1 
SV=3 
23 
Cleavage and polyadenylation specificity factor subunit 2 OS=Mus musculus 
GN=Cpsf2 PE=1 SV=1,Cleavage and polyadenylation specificity factor subunit 2 
OS=Bos taurus GN=CPSF2 PE=1 SV=1,Cleavage and polyadenylation 
specificity factor subunit 2 OS=Homo sapiens GN=CPSF2 PE=1 SV=2 
24 FL cytokine receptor OS=Homo sapiens GN=FLT3 PE=1 SV=2 
25 Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 SV=1 
26 Integrin alpha-L OS=Homo sapiens GN=ITGAL PE=1 SV=3 
27 
Neurogenic locus notch homolog protein 3 OS=Homo sapiens GN=NOTCH3 
PE=1 SV=1 
28 Ninein OS=Homo sapiens GN=NIN PE=1 SV=3 
29 Protein Shroom3 OS=Homo sapiens GN=SHROOM3 PE=1 SV=1 
30 Midasin OS=Homo sapiens GN=MDN1 PE=1 SV=2 
 
 
 
